51
|
Olluri A. Anti-amyloid-beta treatments in Alzheimer's disease: When neurologists turn into cheerleaders. Clin Neurol Neurosurg 2024; 239:108237. [PMID: 38493550 DOI: 10.1016/j.clineuro.2024.108237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Revised: 03/06/2024] [Accepted: 03/07/2024] [Indexed: 03/19/2024]
Affiliation(s)
- Andi Olluri
- University of Gothenburg Sahlgrenska Academy, Department of Internal Medicine and Clinical Nutrition, University of Gothenburg Sahlgrenska Academy, Medicinaregatan, Gothenburg 41390, Sweden.
| |
Collapse
|
52
|
Chen K, Wang M, Wu J, Zuo C, Huang Y, Wang W, Zhao M, Zhang Y, Zhang X, Chen S, Liu W, Li M, Ge J, Ma X, Wang J, Zheng L, Guan Y, Dong Q, Cui M, Xie F, Zhao Q, Yu J. Incremental value of amyloid PET in a tertiary memory clinic setting in China. Alzheimers Dement 2024; 20:2516-2525. [PMID: 38329281 PMCID: PMC11032579 DOI: 10.1002/alz.13728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Revised: 01/04/2024] [Accepted: 01/05/2024] [Indexed: 02/09/2024]
Abstract
INTRODUCTION The objective of this study is to investigate the incremental value of amyloid positron emission tomography (Aβ-PET) in a tertiary memory clinic setting in China. METHODS A total of 1073 patients were offered Aβ-PET using 18F-florbetapir. The neurologists determined a suspected etiology (Alzheimer's disease [AD] or non-AD) with a percentage estimate of their confidence and medication prescription both before and after receiving the Aβ-PET results. RESULTS After disclosure of the Aβ-PET results, etiological diagnoses changed in 19.3% of patients, and diagnostic confidence increased from 69.3% to 85.6%. Amyloid PET results led to a change of treatment plan in 36.5% of patients. Compared to the late-onset group, the early-onset group had a more frequent change in diagnoses and a higher increase in diagnostic confidence. DISCUSSION Aβ-PET has significant impacts on the changes of diagnoses and management in Chinese population. Early-onset cases are more likely to benefit from Aβ-PET than late-onset cases. HIGHLIGHTS Amyloid PET contributes to diagnostic changes and its confidence in Chinese patients. Amyloid PET leads to a change of treatment plans in Chinese patients. Early-onset cases are more likely to benefit from amyloid PET than late-onset cases.
Collapse
Affiliation(s)
- Ke‐Liang Chen
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Ming‐Yu Wang
- School of MedicineQingdao UniversityQingdaoShandongChina
- Departments of NeurologyWeifang People's HospitalWeifangShandongChina
| | - Jie Wu
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Chuan‐Tao Zuo
- Department of Nuclear Medicine & PET CenterHuashan HospitalFudan UniversityShanghaiChina
| | - Yu‐Yuan Huang
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Wei‐Yi Wang
- Department of Nuclear Medicine & PET CenterHuashan HospitalFudan UniversityShanghaiChina
| | - Meng Zhao
- Department of Neurologythe First Hospital of Jilin UniversityChangchunJilinChina
| | - Ya‐Ru Zhang
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Xue Zhang
- Department of NeurologyQingdao shi zhongxin yiyuanQingdaoShandongChina
| | - Shu‐Fen Chen
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Wei‐Shi Liu
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Meng‐Meng Li
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Jing‐Jie Ge
- Department of Nuclear Medicine & PET CenterHuashan HospitalFudan UniversityShanghaiChina
| | - Xiao‐Xi Ma
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Jie Wang
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Li Zheng
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Yi‐Hui Guan
- Department of Nuclear Medicine & PET CenterHuashan HospitalFudan UniversityShanghaiChina
| | - Qiang Dong
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Mei Cui
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Fang Xie
- Department of Nuclear Medicine & PET CenterHuashan HospitalFudan UniversityShanghaiChina
| | - Qian‐Hua Zhao
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| | - Jin‐Tai Yu
- Department of Neurology and National Center for Neurological DiseasesHuashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan UniversityShanghaiChina
| |
Collapse
|
53
|
Mayer J, Boeck D, Werner M, Frankenhauser D, Geley S, Farhan H, Shimozawa M, Nilsson P. Inhibition of Autophagy Alters Intracellular Transport of APP Resulting in Increased APP Processing. Traffic 2024; 25:e12934. [PMID: 38613404 DOI: 10.1111/tra.12934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 03/03/2024] [Accepted: 03/19/2024] [Indexed: 04/14/2024]
Abstract
Alzheimer's disease (AD) pathology is characterized by amyloid beta (Aβ) plaques and dysfunctional autophagy. Aβ is generated by sequential proteolytic cleavage of amyloid precursor protein (APP), and the site of intracellular APP processing is highly debated, which may include autophagosomes. Here, we investigated the involvement of autophagy, including the role of ATG9 in APP intracellular trafficking and processing by applying the RUSH system, which allows studying the transport of fluorescently labeled mCherry-APP-EGFP in a systematic way, starting from the endoplasmic reticulum. HeLa cells, expressing the RUSH mCherry-APP-EGFP system, were investigated by live cell imaging, immunofluorescence, and Western blot. We found that mCherry-APP-EGFP passed through the Golgi faster in ATG9 knockout cells. Furthermore, ATG9 deletion shifted mCherry-APP-EGFP from early endosomes and lysosomes toward the plasma membrane concomitant with reduced endocytosis. Importantly, this alteration in mCherry-APP-EGFP transport resulted in increased secreted mCherry-soluble APP and C-terminal fragment-EGFP. These effects were also phenocopied by pharmacological inhibition of ULK1, indicating that autophagy is regulating the intracellular trafficking and processing of APP. These findings contribute to the understanding of the role of autophagy in APP metabolism and could potentially have implications for new therapeutic approaches for AD.
Collapse
Affiliation(s)
- Johanna Mayer
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden
| | - Dominik Boeck
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden
- Institute of Molecular Neurogenetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Michelle Werner
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden
| | | | - Stephan Geley
- Institute of Pathophysiology, Innsbruck Medical University, Innsbruck, Austria
| | - Hesso Farhan
- Institute of Pathophysiology, Innsbruck Medical University, Innsbruck, Austria
| | - Makoto Shimozawa
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden
| | - Per Nilsson
- Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden
| |
Collapse
|
54
|
Gordón Pidal JM, Moreno-Guzmán M, Montero-Calle A, Valverde A, Pingarrón JM, Campuzano S, Calero M, Barderas R, López MÁ, Escarpa A. Micromotor-based electrochemical immunoassays for reliable determination of amyloid-β (1-42) in Alzheimer's diagnosed clinical samples. Biosens Bioelectron 2024; 249:115988. [PMID: 38194814 DOI: 10.1016/j.bios.2023.115988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 12/22/2023] [Accepted: 12/27/2023] [Indexed: 01/11/2024]
Abstract
Alzheimer's disease (AD), in addition to being the most common cause of dementia, is very difficult to diagnose, with the 42-amino acid form of Aβ (Aβ-42) being one of the main biomarkers used for this purpose. Despite the enormous efforts made in recent years, the technologies available to determine Aβ-42 in human samples require sophisticated instrumentation, present high complexity, are sample and time-consuming, and are costly, highlighting the urgent need not only to develop new tools to overcome these limitations but to provide an early detection and treatment window for AD, which is a top-challenge. In recent years, micromotor (MM) technology has proven to add a new dimension to clinical biosensing, enabling ultrasensitive detections in short times and microscale environments. To this end, here an electrochemical immunoassay based on polypyrrole (PPy)/nickel (Ni)/platinum nanoparticles (PtNPs) MM is proposed in a pioneering manner for the determination of Aβ-42 in left prefrontal cortex brain tissue, cerebrospinal fluid, and plasma samples from patients with AD. MM combines the high binding capacity of their immunorecognition external layer with self-propulsion through the catalytic generation of oxygen bubbles in the internal layer due to decomposition of hydrogen peroxide as fuel, allowing rapid bio-detection (15 min) of Aβ-42 with excellent selectivity and sensitivity (LOD = 0.06 ng/mL). The application of this disruptive technology to the analysis of just 25 μL of the three types of clinical samples provides values concordant with the clinical values reported, thus confirming the potential of the MM approach to assist in the reliable, simple, fast, and affordable diagnosis of AD by determining Aβ-42.
Collapse
Affiliation(s)
- José M Gordón Pidal
- Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, Faculty of Sciences, University of Alcalá, Ctra. Madrid-Barcelona, Km. 33.600, Alcalá de Henares, 28802, Madrid, Spain
| | - María Moreno-Guzmán
- Department of Chemistry in Pharmaceutical Sciences, Analytical Chemistry, Faculty of Pharmacy, Complutense University of Madrid, Plaza Ramón y Cajal, s/n, 28040, Madrid, Spain
| | - Ana Montero-Calle
- Chronic Disease Programme, UFIEC, Carlos III Health Institute, Majadahonda, Madrid, 28220, Spain
| | - Alejandro Valverde
- Department of Analytical Chemistry, Faculty of Chemistry Science, Complutense University of Madrid, Pza. de las Ciencias 2, Madrid, 28040, Spain
| | - José M Pingarrón
- Department of Analytical Chemistry, Faculty of Chemistry Science, Complutense University of Madrid, Pza. de las Ciencias 2, Madrid, 28040, Spain
| | - Susana Campuzano
- Department of Analytical Chemistry, Faculty of Chemistry Science, Complutense University of Madrid, Pza. de las Ciencias 2, Madrid, 28040, Spain.
| | - Miguel Calero
- Chronic Disease Programme, UFIEC, Carlos III Health Institute, Majadahonda, Madrid, 28220, Spain
| | - Rodrigo Barderas
- Chronic Disease Programme, UFIEC, Carlos III Health Institute, Majadahonda, Madrid, 28220, Spain.
| | - Miguel Ángel López
- Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, Faculty of Sciences, University of Alcalá, Ctra. Madrid-Barcelona, Km. 33.600, Alcalá de Henares, 28802, Madrid, Spain; Chemical Research Institute "Andrés M. Del Rio", University of Alcalá, Madrid, Spain
| | - Alberto Escarpa
- Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering, Faculty of Sciences, University of Alcalá, Ctra. Madrid-Barcelona, Km. 33.600, Alcalá de Henares, 28802, Madrid, Spain; Chemical Research Institute "Andrés M. Del Rio", University of Alcalá, Madrid, Spain.
| |
Collapse
|
55
|
Diaz‐Galvan P, Przybelski SA, Algeciras‐Schimnich A, Figdore DJ, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, Jack CR, Min PH, Jain MK, Miyagawa T, Forsberg LK, Fields JA, Savica R, Graff‐Radford J, Ramanan VK, Jones DT, Botha H, St Louis EK, Knopman DS, Graff‐Radford NR, Ferman TJ, Petersen RC, Lowe VJ, Boeve BF, Kantarci K. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies. Alzheimers Dement 2024; 20:2485-2496. [PMID: 38329197 PMCID: PMC11032523 DOI: 10.1002/alz.13653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/28/2023] [Accepted: 12/01/2023] [Indexed: 02/09/2024]
Abstract
INTRODUCTION Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease. METHODS The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans. RESULTS Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB. DISCUSSION The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.
Collapse
Affiliation(s)
| | | | | | - Dan J. Figdore
- Department of Laboratory Medicine and PathologyMayo ClinicRochesterMinnesotaUSA
| | - Timothy G. Lesnick
- Department of Quantitative Health SciencesMayo ClinicRochesterMinnesotaUSA
| | | | | | | | | | - Paul H Min
- Department of RadiologyMayo ClinicRochesterMinnesotaUSA
| | - Manoj K. Jain
- Department of RadiologyMayo ClinicJacksonvilleFloridaUSA
| | - Toji Miyagawa
- Department of NeurologyMayo ClinicRochesterMinnesotaUSA
| | | | - Julie A. Fields
- Department of Psychiatry and PsychologyMayo ClinicRochesterMinnesotaUSA
| | | | | | | | | | - Hugo Botha
- Department of NeurologyMayo ClinicRochesterMinnesotaUSA
| | - Erik K. St Louis
- Mayo Center for Sleep MedicineMayo ClinicRochesterMinnesotaUSA
- Departments of Neurology and Clinical and Translational ResearchMayo Clinic Southwest WisconsinLa CrosseWisconsinUSA
| | | | | | - Tanis J. Ferman
- Department of Psychiatry & PsychologyMayo ClinicJacksonvilleFloridaUSA
| | - Ronald C. Petersen
- Department of Quantitative Health SciencesMayo ClinicRochesterMinnesotaUSA
- Department of NeurologyMayo ClinicRochesterMinnesotaUSA
| | - Val J. Lowe
- Department of RadiologyMayo ClinicRochesterMinnesotaUSA
| | | | | |
Collapse
|
56
|
Momota Y, Bun S, Hirano J, Kamiya K, Ueda R, Iwabuchi Y, Takahata K, Yamamoto Y, Tezuka T, Kubota M, Seki M, Shikimoto R, Mimura Y, Kishimoto T, Tabuchi H, Jinzaki M, Ito D, Mimura M. Amyloid-β prediction machine learning model using source-based morphometry across neurocognitive disorders. Sci Rep 2024; 14:7633. [PMID: 38561395 PMCID: PMC10984960 DOI: 10.1038/s41598-024-58223-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 03/26/2024] [Indexed: 04/04/2024] Open
Abstract
Previous studies have developed and explored magnetic resonance imaging (MRI)-based machine learning models for predicting Alzheimer's disease (AD). However, limited research has focused on models incorporating diverse patient populations. This study aimed to build a clinically useful prediction model for amyloid-beta (Aβ) deposition using source-based morphometry, using a data-driven algorithm based on independent component analyses. Additionally, we assessed how the predictive accuracies varied with the feature combinations. Data from 118 participants clinically diagnosed with various conditions such as AD, mild cognitive impairment, frontotemporal lobar degeneration, corticobasal syndrome, progressive supranuclear palsy, and psychiatric disorders, as well as healthy controls were used for the development of the model. We used structural MR images, cognitive test results, and apolipoprotein E status for feature selection. Three-dimensional T1-weighted images were preprocessed into voxel-based gray matter images and then subjected to source-based morphometry. We used a support vector machine as a classifier. We applied SHapley Additive exPlanations, a game-theoretical approach, to ensure model accountability. The final model that was based on MR-images, cognitive test results, and apolipoprotein E status yielded 89.8% accuracy and a receiver operating characteristic curve of 0.888. The model based on MR-images alone showed 84.7% accuracy. Aβ-positivity was correctly detected in non-AD patients. One of the seven independent components derived from source-based morphometry was considered to represent an AD-related gray matter volume pattern and showed the strongest impact on the model output. Aβ-positivity across neurological and psychiatric disorders was predicted with moderate-to-high accuracy and was associated with a probable AD-related gray matter volume pattern. An MRI-based data-driven machine learning approach can be beneficial as a diagnostic aid.
Collapse
Affiliation(s)
- Yuki Momota
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
- Department of Functional Brain Imaging Research, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-Ku, Chiba-Shi, Chiba, 263-8555, Japan
| | - Shogyoku Bun
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
| | - Jinichi Hirano
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
| | - Kei Kamiya
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Ryo Ueda
- Office of Radiation Technology, Keio University Hospital, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Yu Iwabuchi
- Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Keisuke Takahata
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
- Department of Functional Brain Imaging Research, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-Ku, Chiba-Shi, Chiba, 263-8555, Japan
| | - Yasuharu Yamamoto
- Department of Functional Brain Imaging Research, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-Ku, Chiba-Shi, Chiba, 263-8555, Japan
| | - Toshiki Tezuka
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Masahito Kubota
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Morinobu Seki
- Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Ryo Shikimoto
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Yu Mimura
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Taishiro Kishimoto
- Psychiatry Department, Donald and Barbara Zucker School of Medicine, Hempstead, NY, 11549, USA
- Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Mori JP Tower F7, 1-3-1 Azabudai, Minato-ku, Tokyo, 106-0041, Japan
| | - Hajime Tabuchi
- Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Masahiro Jinzaki
- Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Daisuke Ito
- Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
- Memory Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan
| | - Masaru Mimura
- Center for Preventive Medicine, Keio University, Mori JP Tower 7th Floor, 1-3-1 Azabudai, Minato-ku, Tokyo, 106-0041, Japan
| |
Collapse
|
57
|
Parashar A, Jha D, Mehta V, Chauhan B, Ghosh P, Deb PK, Jaiswal M, Prajapati SK. Sonic hedgehog signalling pathway contributes in age-related disorders and Alzheimer's disease. Ageing Res Rev 2024; 96:102271. [PMID: 38492808 DOI: 10.1016/j.arr.2024.102271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 03/10/2024] [Accepted: 03/11/2024] [Indexed: 03/18/2024]
Abstract
Alzheimer's disease (AD) is caused by the aging process and manifested by cognitive deficits and progressive memory loss. During aging, several conditions, including hypertension, diabetes, and cholesterol, have been identified as potential causes of AD by affecting Sonic hedgehog (Shh) signalling. In addition to being essential for cell differentiation and proliferation, Shh signalling is involved in tissue repair and the prevention of neurodegeneration. Neurogenesis is dependent on Shh signalling; inhibition of this pathway results in neurodegeneration. Several protein-protein interactions that are involved in Shh signalling are implicated in the pathophysiology of AD like overexpression of the protein nexin-1 inhibits the Shh pathway in AD. A protein called Growth Arrest Specific-1 works with another protein called cysteine dioxygenase (CDO) to boost Shh signalling. CDO is involved in the development of the central nervous system (CNS). Shh signalling strengthened the blood brain barrier and therefore prevent the entry of amyloid beta and other toxins to the brain from periphery. Further, several traditional remedies used for AD and dementia, including Epigallocatechin gallate, yokukansan, Lycium barbarum polysaccharides, salvianolic acid, and baicalin, are known to stimulate the Shh pathway. In this review, we elaborated that the Shh signalling exerts a substantial influence on the pathogenesis of AD. In this article, we have tried to explore the various possible connections between the Shh signalling and various known pathologies of AD.
Collapse
Affiliation(s)
- Arun Parashar
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology & Management Sciences, Solan 173 212, India.
| | - Dhruv Jha
- Birla Institute of Technology, India
| | - Vineet Mehta
- Department of Pharmacology, Government College of Pharmacy, Rohru, District Shimla, Himachal Pradesh 171207, India
| | - Bonney Chauhan
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology & Management Sciences, Solan 173 212, India
| | - Pappu Ghosh
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology & Management Sciences, Solan 173 212, India
| | - Prashanta Kumar Deb
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology & Management Sciences, Solan 173 212, India
| | | | | |
Collapse
|
58
|
Blood-based biomarkers for Alzheimer's disease. Neuroscientist 2024; 30:155. [PMID: 38465455 DOI: 10.1177/10738584241236157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
|
59
|
Kassab AE, Gedawy EM, Sayed AS. Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation. Int J Biol Macromol 2024; 265:131018. [PMID: 38518928 DOI: 10.1016/j.ijbiomac.2024.131018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 03/17/2024] [Accepted: 03/18/2024] [Indexed: 03/24/2024]
Abstract
As a "silent threat," Alzheimer's disease (AD) is quickly rising to the top of the list of costly and troublesome diseases facing humanity. It is growing to be one of the most troublesome and expensive conditions, with annual health care costs higher than those of cancer and comparable to those of cardiovascular disorders. One of the main pathogenic characteristics of AD is the deficiency of the neurotransmitter acetylcholine (ACh) which plays a vital role in memory, learning, and attention. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) play a crucial role in hydrolyzing ACh. Consequently, a frequent therapy approach for AD is the suppression of AChE and BChE to improve cholinergic neurotransmission and reduce cognitive symptoms. The accumulation of amyloid plaques (Aβ) is a primary factor contributing to neurodegenerative diseases, particularly AD. Glycogen synthase kinase-3β (GSK3-β) is regarded as a pivotal player in the pathophysiology of AD since dysregulation of this kinase affects all major hallmarks of the disease, such as tau phosphorylation, Aβ aggregation, memory, neurogenesis, and synaptic function. One of the most challenging and risky issues in modern medicinal chemistry is the urgent and ongoing need for the study and development of effective therapeutic candidates for the treatment of AD. A significant class of heterocyclic molecules that can target the complex and multifactorial pathogenesis of AD are fused thiophene derivatives. The goal of the current review is to demonstrate the advancements made in fused thiophene derivatives' anti-AD activity. It also covers their mechanisms of action and studies of the structure-activity relationships in addition to the compilation of significant synthetic routes for fused thiophene derivatives with anti-AD potential. This review is intended to stimulate new ideas in the search for more rationale designs of derivatives based on fused thiophene, hoping to be more potent in treating AD.
Collapse
Affiliation(s)
- Asmaa E Kassab
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, P.O. Box 11562, Egypt.
| | - Ehab M Gedawy
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, P.O. Box 11562, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Pharmaceutical Industries, Badr University in Cairo (BUC), Badr City, Cairo, P.O. Box 11829, Egypt
| | - Alaa S Sayed
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Pharmaceutical Industries, Badr University in Cairo (BUC), Badr City, Cairo, P.O. Box 11829, Egypt
| |
Collapse
|
60
|
Yu F, Pituch KA, Maxfield M, Baena E, Geda YE, Pruzin JJ, Coon DW, Shaibi GQ. The associations between type 2 diabetes and plasma biomarkers of Alzheimer's disease in the Health and Aging Brain Study: Health Disparities (HABS-HD). PLoS One 2024; 19:e0295749. [PMID: 38558059 PMCID: PMC10984470 DOI: 10.1371/journal.pone.0295749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 11/28/2023] [Indexed: 04/04/2024] Open
Abstract
Alzheimer's disease (AD) affects Latinos disproportionately. One of the reasons underlying this disparity may be type 2 diabetes (T2D) that is a risk factor for AD. The purpose of this study was to examine the associations of T2D and AD blood biomarkers and the differences in these associations between Mexican Americans and non-Hispanic Whites. This study was a secondary analysis of baseline data from the observational Health and Aging Brain Study: Health Disparities (HABS-HD) that investigated factors underlying health disparities in AD in Mexican Americans in comparison to non-Hispanic Whites. HABS-HD participants were excluded if they had missing data or were large outliers (z-scores >|4|) on a given AD biomarker. Fasting blood glucose and glycosylated hemoglobin (HbA1c) levels were measured from clinical labs. T2D was diagnosed by licensed clinicians. Plasma amyloid-beta 42 and 40 (Aβ42/42) ratio, total tau (t-tau), and neurofilament light (NfL) were measured via ultra-sensitive Simoa assays. The sample sizes were 1,552 for Aβ42/40 ratio, 1,570 for t-tau, and 1,553 for NfL. Mexican Americans were younger (66.6±8.7 vs. 69.5±8.6) and had more female (64.9% female vs. 55.1%) and fewer years of schooling (9.5±4.6 vs. 15.6±2.5) than non-Hispanic Whites. Mexican Americans differed significantly from non-Hispanic Whites in blood glucose (113.5±36.6 vs. 99.2±17.0) and HbA1c (6.33±1.4 vs. 5.51±0.6) levels, T2D diagnosis (35.3% vs. 11.1%), as well as blood Aβ42/40 ratio (.051±.012 vs. .047±.011), t-tau (2.56±.95 vs. 2.33±.90), and NfL levels (16.3±9.5 vs. 20.3±10.3). Blood glucose, blood HbA1c, and T2D diagnosis were not related to Aβ42/40 ratio and t-tau but explained 3.7% of the variation in NfL (p < .001). Blood glucose and T2D diagnosis were not, while HbA1c was positively (b = 2.31, p < .001, β = 0.26), associated with NfL among Mexican Americans. In contrast, blood glucose, HbA1c, and T2D diagnosis were negatively (b = -0.09, p < .01, β = -0.26), not (b = 0.34, p = .71, β = 0.04), and positively (b = 3.32, p < .01, β = 0.33) associated with NfL, respectively in non-Hispanic Whites. To conclude, blood glucose and HbA1c levels and T2D diagnosis are associated with plasma NfL levels, but not plasma Aβ and t-tau levels. These associations differ in an ethnicity-specific manner and need to be further studied as a potential mechanism underlying AD disparities.
Collapse
Affiliation(s)
- Fang Yu
- Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, United States of America
| | - Keenan A. Pituch
- Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, United States of America
| | - Molly Maxfield
- Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, United States of America
| | - Elsa Baena
- Clinical Neuropsychology Department, Barrow Neurological Institute, Phoenix, Arizona, United States of America
| | - Yonas E. Geda
- Department of Neurology and the Franke Neursciene Education Center, Barrow Neurological Institute, Phoenix, Arizona, United States of America
| | - Jeremy J. Pruzin
- Department of Neurology, Banner Alzheimer’s Institute, Phoenix, Arizona, United States of America
| | - David W. Coon
- Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, United States of America
| | - Gabriel Q. Shaibi
- Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, United States of America
| | | |
Collapse
|
61
|
Ishibashi K, Kurihara M, Toyohara J, Ishii K, Iwata A. Pitfalls of Amyloid-Beta PET: Comparisons With 18 F-MK-6240 and 18 F-THK5351 PET. Clin Nucl Med 2024; 49:319-321. [PMID: 38363815 DOI: 10.1097/rlu.0000000000005097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2024]
Abstract
ABSTRACT We present 3 patients as pitfalls of amyloid-beta (Aβ) PET, who underwent 11 C-PiB (Aβ), 18 F-MK-6240 (Alzheimer disease [AD]-tau), and 18 F-THK5351 (astrogliosis) PET examinations. Despite negligible or tiny Aβ pathology, patients 1 and 2 were diagnosed with AD as the cause of symptoms. Despite widespread Aβ pathology, patient 3 was not diagnosed with AD as the cause of symptoms. However, if we had only conducted Aβ PET, patients 1 and 2 might not have been diagnosed with AD, whereas patient 3 might have been diagnosed with AD. Hence, both Aβ and AD-tau assessments are necessary to relate clinical symptoms to AD pathology.
Collapse
Affiliation(s)
| | - Masanori Kurihara
- Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan
| | | | | | - Atsushi Iwata
- Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan
| |
Collapse
|
62
|
Robinson B, Bhamidi S, Dayan E. The spatial distribution of coupling between tau and neurodegeneration in amyloid-β positive mild cognitive impairment. Neurobiol Aging 2024; 136:70-77. [PMID: 38330641 PMCID: PMC10940182 DOI: 10.1016/j.neurobiolaging.2024.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 01/24/2024] [Accepted: 01/26/2024] [Indexed: 02/10/2024]
Abstract
Synergies between amyloid-β (Aβ), tau, and neurodegeneration persist along the Alzheimer's disease (AD) continuum. This study aimed to evaluate the extent of spatial coupling between tau and neurodegeneration (atrophy) and its relation to Aβ positivity in mild cognitive impairment (MCI). Data from 409 participants were included (95 cognitively normal controls, 158 Aβ positive (Aβ+) MCI, and 156 Aβ negative (Aβ-) MCI). Florbetapir PET, Flortaucipir PET, and structural MRI were used as biomarkers for Aβ, tau and atrophy, respectively. Individual correlation matrices for tau load and atrophy were used to layer a multilayer network, with separate layers for tau and atrophy. A measure of coupling between corresponding regions of interest (ROIs) in the tau and atrophy layers was computed, as a function of Aβ positivity. Fewer than 25% of the ROIs across the brain showed heightened coupling between tau and atrophy in Aβ+ , relative to Aβ- MCI. Coupling strengths in the right rostral middle frontal and right paracentral gyri, in particular, mediated the association between Aβ burden and cognition in this sample.
Collapse
Affiliation(s)
- Belfin Robinson
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
| | - Shankar Bhamidi
- Department of Statistics and Operations Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Eran Dayan
- Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
| |
Collapse
|
63
|
Sakai K, Yamada M. [Neuropathology of Disorders Leading to Dementia]. Brain Nerve 2024; 76:333-342. [PMID: 38589278 DOI: 10.11477/mf.1416202610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/10/2024]
Abstract
Dementia is characterized by acquired cognitive dysfunction caused by various neurological disorders. Many neurological conditions can cause dementia, including neurodegenerative diseases, vascular disorders, infections, inflammation, demyelination, intoxication, metabolic disorders, tumors, and head trauma. Despite recent developments in biomarkers and imaging techniques, neuropathological examination is necessary for the final diagnosis. Moreover, approximately 11% of the patients with dementia have dual or triple pathological conditions. The coexistence of neurological diseases makes it difficult for neurologists to diagnose patients accurately. Degenerative diseases are characterized by neuronal loss with gliosis in distinct parts of the brain, the presence of neuronal or glial inclusions, and abnormal protein accumulation. Senile plaques and neurofibrillary tangles are neuropathological hallmarks of Alzheimer's disease. These findings are characterized by the presence of amyloid β protein (Aβ) and phosphorylated tau protein, respectively. Although vascular dementia is common, it may be difficult to identify the relationship between vascular lesions and cognitive impairment. The incidence of sporadic Aβ-type cerebral amyloid angiopathy (CAA) tends to increase with age and causes dementia due to vascular dysfunction and leukoencephalopathy. Furthermore, patients with CAA can develop inflammation. Clinical neurologists should possess a neuropathological perspective for the appropriate diagnosis and management of patients with dementia.
Collapse
Affiliation(s)
- Kenji Sakai
- Department of Neurology, Joetsu General Hospital
| | | |
Collapse
|
64
|
Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G, Arslan B, Rahmouni N, Tissot C, Servaes S, Stevenson J, Macedo AC, Pascoal TA, Kolb HC, Jeromin A, Blennow K, Zetterberg H, Rosa-Neto P, Benedet AL. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology. EBioMedicine 2024; 102:105046. [PMID: 38471397 PMCID: PMC10943661 DOI: 10.1016/j.ebiom.2024.105046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 02/19/2024] [Accepted: 02/21/2024] [Indexed: 03/14/2024] Open
Abstract
BACKGROUND Blood-based biomarkers of Alzheimer's disease (AD) have become increasingly important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 is the most promising due to its excellent sensitivity and specificity for AD-related pathological changes. METHODS We compared the performance of two commercially available plasma p-tau217 assays (ALZpath p-tau217 and Janssen p-tau217+) in 294 individuals cross-sectionally. Correlations with amyloid PET and tau PET were assessed, and Receiver Operating Characteristic (ROC) analyses evaluated both p-tau217 assays for identifying AD pathology. FINDINGS Both plasma p-tau217 assays were strongly associated with amyloid and tau PET. Furthermore, both plasma p-tau217 assays identified individuals with AD vs other neurodegenerative diseases (ALZpath AUC = 0.95; Janssen AUC = 0.96). Additionally, plasma p-tau217 concentrations rose with AD severity and their annual changes correlated with tau PET annual change. INTERPRETATION Both p-tau217 assays had excellent diagnostic performance for AD. Our study supports the future clinical use of commercially-available assays for p-tau217. FUNDING This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Canadian Consortium on Neurodegeneration in Aging, the Alzheimer's Association, Brain Canada Foundation, the Fonds de Recherche du Québec - Santé and the Colin J. Adair Charitable Foundation.
Collapse
Affiliation(s)
- Joseph Therriault
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Nicholas James Ashton
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden; Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg 6 431 41, Sweden; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London SE5 9RT, UK; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London SE5 8AF, UK
| | - Ilaria Pola
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden
| | | | - Wagner Scheeren Brum
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden
| | - Guglielmo Di Molfetta
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden
| | - Burak Arslan
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden
| | - Nesrine Rahmouni
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Cecile Tissot
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Stijn Servaes
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Jenna Stevenson
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Arthur Cassa Macedo
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Tharick Ali Pascoal
- Department of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh 15213, USA
| | | | | | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 6 431 41, Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 6 431 41, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London SE5 9RT, UK; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong 1512, China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA
| | - Pedro Rosa-Neto
- Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec H4H 1R3, Canada; Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec H3A 2B4, Canada
| | - Andrea Lessa Benedet
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal 6 431 41, Sweden.
| |
Collapse
|
65
|
Garcia‐Agudo LF, Shi Z, Smith IF, Kramár EA, Tran K, Kawauchi S, Wang S, Collins S, Walker A, Shi K, Neumann J, Liang HY, Da Cunha C, Milinkeviciute G, Morabito S, Miyoshi E, Rezaie N, Gomez‐Arboledas A, Arvilla AM, Ghaemi DI, Tenner AJ, LaFerla FM, Wood MA, Mortazavi A, Swarup V, MacGregor GR, Green KN. BIN1 K358R suppresses glial response to plaques in mouse model of Alzheimer's disease. Alzheimers Dement 2024; 20:2922-2942. [PMID: 38460121 PMCID: PMC11032570 DOI: 10.1002/alz.13767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 01/16/2024] [Accepted: 01/17/2024] [Indexed: 03/11/2024]
Abstract
INTRODUCTION The BIN1 coding variant rs138047593 (K358R) is linked to Late-Onset Alzheimer's Disease (LOAD) via targeted exome sequencing. METHODS To elucidate the functional consequences of this rare coding variant on brain amyloidosis and neuroinflammation, we generated BIN1K358R knock-in mice using CRISPR/Cas9 technology. These mice were subsequently bred with 5xFAD transgenic mice, which serve as a model for Alzheimer's pathology. RESULTS The presence of the BIN1K358R variant leads to increased cerebral amyloid deposition, with a dampened response of astrocytes and oligodendrocytes, but not microglia, at both the cellular and transcriptional levels. This correlates with decreased neurofilament light chain in both plasma and brain tissue. Synaptic densities are significantly increased in both wild-type and 5xFAD backgrounds homozygous for the BIN1K358R variant. DISCUSSION The BIN1 K358R variant modulates amyloid pathology in 5xFAD mice, attenuates the astrocytic and oligodendrocytic responses to amyloid plaques, decreases damage markers, and elevates synaptic densities. HIGHLIGHTS BIN1 rs138047593 (K358R) coding variant is associated with increased risk of LOAD. BIN1 K358R variant increases amyloid plaque load in 12-month-old 5xFAD mice. BIN1 K358R variant dampens astrocytic and oligodendrocytic response to plaques. BIN1 K358R variant decreases neuronal damage in 5xFAD mice. BIN1 K358R upregulates synaptic densities and modulates synaptic transmission.
Collapse
Affiliation(s)
| | - Zechuan Shi
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
| | - Ian F. Smith
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
| | - Enikö A. Kramár
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
| | - Katelynn Tran
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Shimako Kawauchi
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
| | - Shuling Wang
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
| | - Sherilyn Collins
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
| | - Amber Walker
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
| | - Kai‐Xuan Shi
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
| | - Jonathan Neumann
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
| | - Heidi Yahan Liang
- Department of Developmental and Cell BiologyUniversity of CaliforniaIrvineCaliforniaUSA
- Center for Complex Biological Systems, University of CaliforniaIrvineCaliforniaUSA
| | - Celia Da Cunha
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Giedre Milinkeviciute
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Samuel Morabito
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
| | - Emily Miyoshi
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
| | - Narges Rezaie
- Department of Developmental and Cell BiologyUniversity of CaliforniaIrvineCaliforniaUSA
- Center for Complex Biological Systems, University of CaliforniaIrvineCaliforniaUSA
| | - Angela Gomez‐Arboledas
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Adrian Mendoza Arvilla
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Daryan Iman Ghaemi
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
| | - Andrea J. Tenner
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
- Department of Molecular Biology & BiochemistryUniversity of CaliforniaIrvineCaliforniaUSA
- Department of Pathology and Laboratory MedicineUniversity of CaliforniaIrvineCaliforniaUSA
| | - Frank M. LaFerla
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Marcelo A. Wood
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| | - Ali Mortazavi
- Department of Developmental and Cell BiologyUniversity of CaliforniaIrvineCaliforniaUSA
- Center for Complex Biological Systems, University of CaliforniaIrvineCaliforniaUSA
| | - Vivek Swarup
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
- Center for Complex Biological Systems, University of CaliforniaIrvineCaliforniaUSA
| | - Grant R. MacGregor
- Transgenic Mouse Facility, ULAR, Office of Research, University of CaliforniaIrvineCaliforniaUSA
- Department of Developmental and Cell BiologyUniversity of CaliforniaIrvineCaliforniaUSA
| | - Kim N. Green
- Department of Neurobiology and BehaviorUniversity of CaliforniaIrvineCaliforniaUSA
- Institute for Memory Impairments and Neurological Disorders, University of CaliforniaIrvineCaliforniaUSA
| |
Collapse
|
66
|
Li Q, Wang J, Cui R, Yuan J. Identifying Mixed Dementia With Lewy Bodies and Alzheimer Disease Using Multitracer PET Imaging: A Case Study. Clin Nucl Med 2024; 49:364-365. [PMID: 38350092 DOI: 10.1097/rlu.0000000000005081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2024]
Abstract
ABSTRACT We reported imaging findings with complex signs that were corresponded with both dementia with Lewy bodies (DLB) and Alzheimer disease (AD) in the case of a 78-year-old woman. Initially suspected as DLB due to cognitive and movement issues, diagnostic support included the cingulate island sign on 18 F-FDG PET, positive 131 I-MIBG cardiac scintigraphy, and DAT PET. However, MRI indicated hippocampal atrophy, and 18 F-FDG PET showed hypometabolism in the medial temporal lobe, suggesting the possibility of concomitant AD. Subsequent detection of β-amyloid pathology and tau accumulation in the brain further supported the concurrent presence of AD pathology.
Collapse
Affiliation(s)
| | - Junshan Wang
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Jing Yuan
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
67
|
Li J, Shan W, Zuo Z. Co-housing with Alzheimer's disease mice induces changes in gut microbiota and impairment of learning and memory in control mice. CNS Neurosci Ther 2024; 30:e14491. [PMID: 37789692 PMCID: PMC11017403 DOI: 10.1111/cns.14491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 09/08/2023] [Accepted: 09/24/2023] [Indexed: 10/05/2023] Open
Affiliation(s)
- Jun Li
- Department of AnesthesiologyUniversity of VirginiaCharlottesvilleVirginiaUSA
| | - Weiran Shan
- Department of AnesthesiologyUniversity of VirginiaCharlottesvilleVirginiaUSA
| | - Zhiyi Zuo
- Department of AnesthesiologyUniversity of VirginiaCharlottesvilleVirginiaUSA
| |
Collapse
|
68
|
Fonseca CS, Baker SL, Dobyns L, Janabi M, Jagust WJ, Harrison TM. Tau accumulation and atrophy predict amyloid independent cognitive decline in aging. Alzheimers Dement 2024; 20:2526-2537. [PMID: 38334195 PMCID: PMC11032527 DOI: 10.1002/alz.13654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 11/15/2023] [Accepted: 11/30/2023] [Indexed: 02/10/2024]
Abstract
INTRODUCTION Amyloid beta (Aβ) and tau pathology are cross-sectionally associated with atrophy and cognitive decline in aging and Alzheimer's disease (AD). METHODS We investigated relationships between concurrent longitudinal measures of Aβ (Pittsburgh compound B [PiB] positron emission tomography [PET]), tau (flortaucipir [FTP] PET), atrophy (structural magnetic resonance imaging), episodic memory (EM), and non-memory (NM) in 78 cognitively healthy older adults (OA). RESULTS Entorhinal FTP change was correlated with EM decline regardless of Aβ, but meta-temporal FTP and global PiB change were only associated with EM and NM decline in Aβ+ OA. Voxel-wise analyses revealed significant associations between temporal lobe FTP change and EM decline in all groups. PiB and FTP change were not associated with structural change, suggesting a functional or microstructural mechanism linking these measures to cognitive decline. DISCUSSION Our results show that longitudinal Aβ is linked to cognitive decline only in the presence of elevated Aβ, but longitudinal temporal lobe tau is associated with memory decline regardless of Aβ status. HIGHLIGHTS Entorhinal tau change was associated with memory decline in older adults (OA), regardless of amyloid beta (Aβ). Greater meta-region of interest (ROI) tau change correlated with memory decline in Aβ+ OA. Voxel-wise temporal tau change correlated with memory decline, regardless of Aβ. Meta-ROI tau and global amyloid change correlated with non-memory change in Aβ+ OA. Tau and amyloid accumulation were not associated with structural change in OA.
Collapse
Affiliation(s)
- Corrina S. Fonseca
- Helen Wills Neuroscience InstituteUniversity of CaliforniaBerkeleyCaliforniaUSA
| | | | - Lindsey Dobyns
- Helen Wills Neuroscience InstituteUniversity of CaliforniaBerkeleyCaliforniaUSA
| | - Mustafa Janabi
- Lawrence Berkeley National LaboratoryBerkeleyCaliforniaUSA
| | - William J. Jagust
- Helen Wills Neuroscience InstituteUniversity of CaliforniaBerkeleyCaliforniaUSA
- Lawrence Berkeley National LaboratoryBerkeleyCaliforniaUSA
| | - Theresa M. Harrison
- Helen Wills Neuroscience InstituteUniversity of CaliforniaBerkeleyCaliforniaUSA
| |
Collapse
|
69
|
Valipour B, Simorgh S, Mirsalehi M, Moradi S, Taghizadeh-Hesary F, Seidkhani E, Akbarnejad Z, Alizadeh R. Improvement of spatial learning and memory deficits by intranasal administration of human olfactory ecto-mesenchymal stem cells in an Alzheimer's disease rat model. Brain Res 2024; 1828:148764. [PMID: 38242524 DOI: 10.1016/j.brainres.2024.148764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 12/14/2023] [Accepted: 01/09/2024] [Indexed: 01/21/2024]
Abstract
Mesenchymal stem cells therapy provides a new perspective of therapeutic approaches in the treatment of neurodegenerative diseases. The present study aimed to investigate the effects of intranasally transplanted human "olfactory ecto-mesenchymal stem cells" (OE-MSCs) in Alzheimer's disease (AD) rats. In this study, we isolated OE-MSCs from human olfactory lamina propria and phenotypically characterized them using immunocytochemistry and flow cytometry. The undifferentiated OE-MSCs were transplanted either by intranasal (IN) or intrahippocampal (IH) injection to rat models of AD, which were induced by injecting amyloid-beta (Aβ) intrahippocampally. Behavioral, histological, and molecular assessments were performed after a three-month recovery period. Based on the results, intranasal administration of OE-MSCs significantly reduced Aβ accumulation and neuronal loss, improved learning and memory impairments, and increased levels of BDNF (brain-derived neurotrophic factor) and NMDAR (N-methyl-D-Aspartate receptors) in the AD rat model. These changes were more significant in animals who received OE-MSCs by intranasal injection. The results of this study suggest that OE-MSCs have the potential to enhance cognitive function in AD, possibly mediated by BDNF and the NMDA receptors.
Collapse
Affiliation(s)
- Behnaz Valipour
- Department of Anatomical Sciences, Sarab Faculty of Medical Sciences, Sarab, Iran; Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sara Simorgh
- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Marjan Mirsalehi
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Salah Moradi
- Department of Life Science Engineering, Faculty of New Science and Technology, University of Tehran, Tehran, Iran
| | - Farzad Taghizadeh-Hesary
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Elham Seidkhani
- Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Zeinab Akbarnejad
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
| | - Rafieh Alizadeh
- ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
70
|
Lista S, Mapstone M, Caraci F, Emanuele E, López-Ortiz S, Martín-Hernández J, Triaca V, Imbimbo C, Gabelle A, Mielke MM, Nisticò R, Santos-Lozano A, Imbimbo BP. A critical appraisal of blood-based biomarkers for Alzheimer's disease. Ageing Res Rev 2024; 96:102290. [PMID: 38580173 DOI: 10.1016/j.arr.2024.102290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 03/18/2024] [Accepted: 03/31/2024] [Indexed: 04/07/2024]
Abstract
Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the identification of individuals in the early, preclinical stages of the disease. Detecting AD at this point may allow for more effective therapeutic interventions and optimized enrollment for clinical trials of novel drugs. The current biological diagnosis of AD is based on the AT(N) classification system with the measurement of brain deposition of amyloid-β (Aβ) ("A"), tau pathology ("T"), and neurodegeneration ("N"). Diagnostic cut-offs for Aβ1-42, the Aβ1-42/Aβ1-40 ratio, tau and hyperphosphorylated-tau concentrations in cerebrospinal fluid have been defined and may support AD clinical diagnosis. Blood-based biomarkers of the AT(N) categories have been described in the AD continuum. Cross-sectional and longitudinal studies have shown that the combination of blood biomarkers tracking neuroaxonal injury (neurofilament light chain) and neuroinflammatory pathways (glial fibrillary acidic protein) enhance sensitivity and specificity of AD clinical diagnosis and improve the prediction of AD onset. However, no international accepted cut-offs have been identified for these blood biomarkers. A kit for blood Aβ1-42/Aβ1-40 is commercially available in the U.S.; however, it does not provide a diagnosis, but simply estimates the risk of developing AD. Although blood-based AD biomarkers have a great potential in the diagnostic work-up of AD, they are not ready for the routine clinical use.
Collapse
Affiliation(s)
- Simone Lista
- i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid 47012, Spain.
| | - Mark Mapstone
- Department of Neurology, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.
| | - Filippo Caraci
- Department of Drug and Health Sciences, University of Catania, Catania 95125, Italy; Neuropharmacology and Translational Neurosciences Research Unit, Oasi Research Institute-IRCCS, Troina 94018, Italy.
| | | | - Susana López-Ortiz
- i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid 47012, Spain.
| | - Juan Martín-Hernández
- i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid 47012, Spain.
| | - Viviana Triaca
- Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), Rome 00015, Italy.
| | - Camillo Imbimbo
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia 27100, Italy.
| | - Audrey Gabelle
- Memory Resources and Research Center, Montpellier University of Excellence i-site, Montpellier 34295, France.
| | - Michelle M Mielke
- Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
| | - Robert Nisticò
- School of Pharmacy, University of Rome "Tor Vergata", Rome 00133, Italy; Laboratory of Pharmacology of Synaptic Plasticity, EBRI Rita Levi-Montalcini Foundation, Rome 00143, Italy.
| | - Alejandro Santos-Lozano
- i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid 47012, Spain; Physical Activity and Health Research Group (PaHerg), Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid 28041, Spain.
| | - Bruno P Imbimbo
- Department of Research and Development, Chiesi Farmaceutici, Parma 43122, Italy.
| |
Collapse
|
71
|
Wang X, Zhang W, Hou L, Geng W, Wang J, Kong Y, Liu C, Zeng X, Kong D. A Biomimetic Upconversion Nanobait-Based Near Infrared Light Guided Photodynamic Therapy Alleviates Alzheimer's Disease by Inhibiting β-Amyloid Aggregation. Adv Healthc Mater 2024; 13:e2303278. [PMID: 38112336 DOI: 10.1002/adhm.202303278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 12/14/2023] [Indexed: 12/21/2023]
Abstract
Aberrant β-amyloid (Aβ) fibrillation is the key event in Alzheimer's disease (AD), the inhibition and degradation of which are recognized as a promising therapeutic strategy to alleviate the nerve damage of AD. Photodynamic therapy (PDT) holds great potential for modulation of Aβ self-assembly, which is nevertheless limited by the inefficient utilization of reactive oxygen species (ROS). Herein, an erythrocyte membrane (EM)-modified core-shell upconversion nanoparticle (UCNP/Cur@EM) is designed and fabricated as a biomimetic nanobait to improve the PDT efficiency in AD. The UCNP with the outlayer of mesoporous silica is synthesized to load a high amount of the photosensitizer (curcumin), the unique optical feature of which can trigger curcumin to generate ROS upon near-infrared light (NIR) irradiation. Integration of EM enables the biomimetic nanobait to attract Aβ peptides trapped in the phospholipid bilayer, restraining the growth of Aβ monomers to form aggregates and improving the utilization rate of ROS to degrade the preformed Aβ aggregates. In vivo studies demonstrate that UCNP/Cur@EM irradiated by NIR enables to decrease Aβ deposits, ameliorates memory deficits, and rescues cognitive functions in the APP/PS1 transgenic mouse model. A biocompatible and controllable way is provided here to inhibit the amyloid protein-associated pathological process of AD.
Collapse
Affiliation(s)
- Xu Wang
- Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Wenjing Zhang
- Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
- Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin, 300070, China
| | - Lili Hou
- Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
- Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin, 300070, China
| | - Wei Geng
- Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Jingwen Wang
- Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
| | - Yu Kong
- Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin, 300070, China
| | - Chang Liu
- Tianjin Key Laboratory for Photoelectric Materials and Devices, School of Materials Science & Engineering, Tianjin University of Technology, Tianjin, 300384, China
| | - Xianshun Zeng
- Tianjin Key Laboratory for Photoelectric Materials and Devices, School of Materials Science & Engineering, Tianjin University of Technology, Tianjin, 300384, China
| | - Dexin Kong
- Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China
- Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education), Tianjin Medical University, Tianjin, 300070, China
| |
Collapse
|
72
|
Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, Zetterberg H, Bateman RJ, Scheltens P, Blennow K, Sperling R, Hansson O, Jack CR, Rosa-Neto P. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol 2024; 20:232-244. [PMID: 38429551 DOI: 10.1038/s41582-024-00942-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/05/2024] [Indexed: 03/03/2024]
Abstract
Disease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. Current in vivo diagnostic frameworks for AD are based on abnormal concentrations of amyloid-β and tau in the cerebrospinal fluid or on PET scans, and breakthroughs in molecular imaging have opened up the possibility of in vivo staging of AD. Focusing on the key principles of disease staging shared across several areas of medicine, this Review highlights the potential for in vivo staging of AD to transform our understanding of preclinical AD, refine enrolment criteria for trials of disease-modifying therapies and aid clinical decision-making in the era of anti-amyloid therapeutics. We provide a state-of-the-art review of recent biomarker-based AD staging systems and highlight their contributions to the understanding of the natural history of AD. Furthermore, we outline hypothetical frameworks to stage AD severity using more accessible fluid biomarkers. In addition, by applying amyloid PET-based staging to recently published anti-amyloid therapeutic trials, we highlight how biomarker-based disease staging frameworks could illustrate the numerous pathological changes that have already taken place in individuals with mildly symptomatic AD. Finally, we discuss challenges related to the validation and standardization of disease staging and provide a forward-looking perspective on potential clinical applications.
Collapse
Affiliation(s)
- Joseph Therriault
- Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montreal, Quebec, Canada.
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
| | - Suzanne E Schindler
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
| | - Gemma Salvadó
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
| | - Tharick A Pascoal
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Andréa Lessa Benedet
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
| | - Nicholas J Ashton
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- NIHR Biomedical Research Centre, South London and Maudsley NHS Foundation, London, UK
| | - Thomas K Karikari
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
| | - Liana Apostolova
- Department of Neurology, University of Indiana School of Medicine, Indianapolis, IN, USA
| | | | - Inge Verberk
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Jacob W Vogel
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
- Department of Clinical Sciences, Malmö, SciLifeLab, Lund University, Lund, Sweden
| | - Renaud La Joie
- Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
| | - Serge Gauthier
- Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montreal, Quebec, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| | - Charlotte Teunissen
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Gil D Rabinovici
- Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
- UK Dementia Research Institute at UCL, London, UK
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
| | - Randall J Bateman
- Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
- Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
- Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, MO, USA
| | - Philip Scheltens
- Alzheimer Centre Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
| | - Reisa Sperling
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
- Memory Clinic, Skåne University Hospital, Malmö, Sweden
| | | | - Pedro Rosa-Neto
- Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montreal, Quebec, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
73
|
Klein EG, Schroeder K, Wessels AM, Phipps A, Japha M, Schilling T, Zimmer JA. How donanemab data address the coverage with evidence development questions. Alzheimers Dement 2024; 20:3127-3140. [PMID: 38323738 PMCID: PMC11032520 DOI: 10.1002/alz.13700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 12/12/2023] [Accepted: 12/16/2023] [Indexed: 02/08/2024]
Abstract
The Centers for Medicare & Medicaid Services (CMS) established a class-based National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for Alzheimer's disease (AD) with patient access through Coverage with Evidence Development (CED) based on three questions. This review, focused on donanemab, answers each of these CED questions with quality evidence. TRAILBLAZER-ALZ registration trials are presented with supporting literature and real-world data to answer CED questions for donanemab. TRAILBLAZER-ALZ registration trials demonstrated that donanemab significantly slowed cognitive and functional decline in amyloid-positive early symptomatic AD participants, and lowered their risk of disease progression while key safety risks occurred primarily within the first 6 months and then declined. Donanemab meaningfully improved health outcomes with a manageable safety profile in an early symptomatic AD population, representative of Medicare populations across diverse practice settings. The donanemab data provide the necessary level of evidence for CMS to open a reconsideration of their NCD. HIGHLIGHTS: Donanemab meaningfully improved outcomes in trial participants with early symptomatic Alzheimer's disease. Comorbidities in trial participants were consistent with the Medicare population. Co-medications in trial participants were consistent with the Medicare population. Risks associated with treatment tended to occur in the first 6 months. Risks of amyloid-related imaging abnormalities were managed with careful observation and magnetic resonance imaging monitoring.
Collapse
Affiliation(s)
- Eric G. Klein
- Global Medical Affairs, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| | - Krista Schroeder
- Research and Development, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| | - Alette M. Wessels
- Research and Development, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| | - Adam Phipps
- Lilly Value and Access, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| | - Maureen Japha
- Corporate Affairs, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| | - Traci Schilling
- Global Medical Affairs, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| | - Jennifer A. Zimmer
- Research and Development, Eli Lilly and CompanyLilly Corporate CenterIndianapolisIndianaUSA
| |
Collapse
|
74
|
Gonzalez‐Ortiz F, Karikari TK, Blennow K. Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p-tau217. Alzheimers Dement 2024; 20:3114-3115. [PMID: 38328965 PMCID: PMC11032551 DOI: 10.1002/alz.13708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Accepted: 12/28/2023] [Indexed: 02/09/2024]
Abstract
Alzheimer's disease (AD) represents a growing global health challenge, necessitating accurate and reliable diagnostic methodologies for timely intervention and management. Immunoassays, specifically designed to detect biomarkers associated with AD pathology, have emerged as pivotal tools in diagnostic development. Understanding of the established protocols ensures assay sensitivity, specificity, and reproducibility, thereby enhancing the clinical utility of these diagnostic tools. Here, we explore the considerations in immunoassay development, focusing on phosphorylated tau217 assays. Ultimately, a clear understanding of immunoassay development is paramount in advancing the precision and reliability of AD diagnostics, contributing to early detection, improved patient outcomes, and advancements in therapeutic interventions.
Collapse
Affiliation(s)
- Fernando Gonzalez‐Ortiz
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Sahlgrenska Academy at the University of GothenburgMölndalSweden
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
| | - Thomas K. Karikari
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Sahlgrenska Academy at the University of GothenburgMölndalSweden
- Department of Psychiatry, School of MedicineUniversity of PittsburghPittsburghPennsylvaniaUSA
| | - Kaj Blennow
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Sahlgrenska Academy at the University of GothenburgMölndalSweden
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
| |
Collapse
|
75
|
Hung SM, Adams SW, Molloy C, Wu DA, Shimojo S, Arakaki X. Practice makes imperfect: stronger implicit interference with practice in individuals at high risk of developing Alzheimer's disease. GeroScience 2024; 46:2777-2786. [PMID: 37817004 PMCID: PMC10828369 DOI: 10.1007/s11357-023-00953-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 09/19/2023] [Indexed: 10/12/2023] Open
Abstract
Early screening to determine patient risk of developing Alzheimer's will allow better interventions and planning but necessitates accessible methods such as behavioral biomarkers. Previously, we showed that cognitively healthy older individuals whose cerebrospinal fluid amyloid/tau ratio indicates high risk of cognitive decline experienced implicit interference during a high-effort task, signaling early changes in attention. To further investigate attention's effect on implicit interference, we analyzed two experiments completed sequentially by the same high- and low-risk individuals. We hypothesized that if attention modulates interference, practice would affect the influence of implicit distractors. Indeed, while both groups experienced a strong practice effect, the association between practice and interference effects diverged between groups: stronger practice effects correlated with more implicit interference in high-risk participants, but less interference in low-risk individuals. Furthermore, low-risk individuals showed a positive correlation between implicit interference and EEG low-range alpha event-related desynchronization when switching from high- to low-load tasks. This suggests that lower attention on the task was correlated with stronger interference, a typical phenomenon in the younger population. These results demonstrate how attention impacts implicit interference and highlight early differences in perception between high- and low-risk individuals.
Collapse
Affiliation(s)
- Shao-Min Hung
- Waseda Institute for Advanced Study, Waseda University, Tokyo, Japan.
- Faculty of Science and Engineering, Waseda University, Tokyo, Japan.
- Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
| | - Sara W Adams
- Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA
| | - Cathleen Molloy
- Cognition and Brain Integration Laboratory, Department of Neurosciences, Huntington Medical Research Institutes, Pasadena, CA, USA
| | - Daw-An Wu
- Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA
| | - Shinsuke Shimojo
- Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
- Computation and Neural Systems, California Institute of Technology, Pasadena, CA, USA.
| | - Xianghong Arakaki
- Cognition and Brain Integration Laboratory, Department of Neurosciences, Huntington Medical Research Institutes, Pasadena, CA, USA.
| |
Collapse
|
76
|
Ono K, Shiina H, Matsumoto M, Nakamura Y. [The Roles of Aβ in Alzheimer's Disease: In Light of the Latest Findings]. Brain Nerve 2024; 76:399-408. [PMID: 38589284 DOI: 10.11477/mf.1416202619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/10/2024]
Abstract
The 'amyloid hypothesis', initially put forward in 1992, posits that amyloid β protein (Aβ) contributes to neurodegeneration through aberrant aggregation. In the process of this aberrant aggregation, Aβ forms oligomers, protofibrils, and mature fibrils, ultimately developing plaques. These mature fibrils and plaques were believed to be the culprits behind the neurotoxicity and neurodegeneration seen in Alzheimer's disease (AD). However, growing evidence in recent years has led to the 'Aβ oligomer hypothesis', which suggests that the intermediate forms of aggregates, such as oligomers and protofibrils, exhibit stronger neurotoxicity than the mature forms. Consequently, efforts have been made to develop anti-Aβ antibody drugs that specifically target these intermediate aggregates. Such interventions hold promise as disease-modifying treatments for AD.
Collapse
Affiliation(s)
- Kenjiro Ono
- Department of Neurology, Kanazawa University Graduate School of Medical Sciences
| | | | | | | |
Collapse
|
77
|
Abbatecola AM, Giuliani A, Biscetti L, Scisciola L, Battista P, Barbieri M, Sabbatinelli J, Olivieri F. Circulating biomarkers of inflammaging and Alzheimer's disease to track age-related trajectories of dementia: Can we develop a clinically relevant composite combination? Ageing Res Rev 2024; 96:102257. [PMID: 38437884 DOI: 10.1016/j.arr.2024.102257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 02/27/2024] [Accepted: 02/29/2024] [Indexed: 03/06/2024]
Abstract
Alzheimer's disease (AD) is a rapidly growing global concern due to a consistent rise of the prevalence of dementia which is mainly caused by the aging population worldwide. An early diagnosis of AD remains important as interventions are plausibly more effective when started at the earliest stages. Recent developments in clinical research have focused on the use of blood-based biomarkers for improve diagnosis/prognosis of neurodegenerative diseases, particularly AD. Unlike invasive cerebrospinal fluid tests, circulating biomarkers are less invasive and will become increasingly cheaper and simple to use in larger number of patients with mild symptoms or at risk of dementia. In addition to AD-specific markers, there is growing interest in biomarkers of inflammaging/neuro-inflammaging, an age-related chronic low-grade inflammatory condition increasingly recognized as one of the main risk factor for almost all age-related diseases, including AD. Several inflammatory markers have been associated with cognitive performance and AD development and progression. The presence of senescent cells, a key driver of inflammaging, has also been linked to AD pathogenesis, and senolytic therapy is emerging as a potential treatment strategy. Here, we describe blood-based biomarkers clinically relevant for AD diagnosis/prognosis and biomarkers of inflammaging associated with AD. Through a systematic review approach, we propose that a combination of circulating neurodegeneration and inflammatory biomarkers may contribute to improving early diagnosis and prognosis, as well as providing valuable insights into the trajectory of cognitive decline and dementia in the aging population.
Collapse
Affiliation(s)
- Angela Marie Abbatecola
- Alzheimer's Disease Day Clinic, Azienda Sanitaria Locale, Frosinone, Italy; Univesità degli Studi di Cassino e del Lazio Meridionale, Dipartimento di Scienze Umane, Sociali e della Salute, Cassino, Italy
| | - Angelica Giuliani
- Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit of Bari Institute, Italy.
| | | | - Lucia Scisciola
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Petronilla Battista
- Istituti Clinici Scientifici Maugeri IRCCS, Laboratory of Neuropsychology, Bari Institute, Italy
| | - Michelangela Barbieri
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Jacopo Sabbatinelli
- Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy; Clinic of Laboratory and Precision Medicine, IRCCS INRCA, Ancona, Italy
| | - Fabiola Olivieri
- Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy; Clinic of Laboratory and Precision Medicine, IRCCS INRCA, Ancona, Italy
| |
Collapse
|
78
|
D'Adamio L. Reply to Johansson 'Treatment with BRICHOS domain helps to clarify issues with Alzheimer mouse models'. EMBO Mol Med 2024; 16:717-719. [PMID: 38480931 PMCID: PMC11018735 DOI: 10.1038/s44321-024-00042-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 02/06/2024] [Accepted: 02/09/2024] [Indexed: 03/21/2024] Open
Abstract
This correspondence is a reply to correspondence from Dr. Jan Johansson on the utility of BRICHOS domains in understanding pathology in Alzheimer’s disease mouse models.
Collapse
Affiliation(s)
- Luciano D'Adamio
- Department of Pharmacology, Physiology & Neuroscience New Jersey Medical School, Brain Health Institute, Jacqueline Krieger Klein Center in Alzheimer's Disease and Neurodegeneration Research, Rutgers, The State University of New Jersey, 205 South Orange Ave, Newark, NJ, 07103, USA.
| |
Collapse
|
79
|
Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, Nuñez‐Llaves R, Aguilera N, Ramis M, Simrén J, Nilsson J, Lantero‐Rodriguez J, Orellana A, García‐Gutiérrez F, Morató X, Ashton NJ, Montoliu‐Gaya L. Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings. Alzheimers Dement 2024; 20:2340-2352. [PMID: 38284555 PMCID: PMC11032540 DOI: 10.1002/alz.13697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 12/28/2023] [Accepted: 12/28/2023] [Indexed: 01/30/2024]
Abstract
BACKGROUND We aimed to evaluate the precision of Alzheimer's disease (AD) and neurodegeneration biomarker measurements from venous dried plasma spots (DPSv enous) for the diagnosis and monitoring of neurodegenerative diseases in remote settings. METHODS In a discovery (n = 154) and a validation cohort (n = 115), glial fibrillary acidic protein (GFAP); neurofilament light (NfL); amyloid beta (Aβ) 40, Aβ42; and phosphorylated tau (p-tau181 and p-tau217) were measured in paired DPSvenous and ethylenediaminetetraacetic acid plasma samples with single-molecule array. In the validation cohort, a subset of participants (n = 99) had cerebrospinal fluid (CSF) biomarkers. RESULTS All DPSvenous and plasma analytes correlated significantly, except for Aβ42. In the validation cohort, DPSvenous GFAP, NfL, p-tau181, and p-tau217 differed between CSF Aβ-positive and -negative individuals and were associated with worsening cognition. DISCUSSION Our data suggest that measuring blood biomarkers related to AD pathology and neurodegeneration from DPSvenous extends the utility of blood-based biomarkers to remote settings with simplified sampling conditions, storage, and logistics. HIGHLIGHTS A wide array of biomarkers related to Alzheimer's disease (AD) and neurodegeneration were detectable in dried plasma spots (DPSvenous). DPSvenous biomarkers correlated with standard procedures and cognitive status. DPSvenous biomarkers had a good diagnostic accuracy discriminating amyloid status. Our findings show the potential interchangeability of DPSvenous and plasma sampling. DPSvenous may facilitate remote and temperature-independent sampling for AD biomarker measurement. Innovative tools for blood biomarker sampling may help recognizing the earliest changes of AD.
Collapse
Affiliation(s)
- Hanna Huber
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
| | - Kaj Blennow
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
| | - Henrik Zetterberg
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
- Department of Neurodegenerative DiseaseUCL Institute of NeurologyLondonUK
- UK Dementia Research InstituteUCLLondonUK
- Hong Kong Center for Neurodegenerative DiseasesHong KongChina
- Wisconsin Alzheimer's Disease Research CenterUniversity of Wisconsin School of Medicine and Public HealthMadisonWisconsinUSA
| | - Mercé Boada
- Networking Research Center on Neurodegenerative Diseases (CIBERNED)Instituto de Salud Carlos IIIMadridSpain
- Ace Alzheimer Center BarcelonaInternational University of Catalunya (UIC)BarcelonaSpain
| | | | - Haley Weninger
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
| | - Raul Nuñez‐Llaves
- Ace Alzheimer Center BarcelonaInternational University of Catalunya (UIC)BarcelonaSpain
| | - Núria Aguilera
- Ace Alzheimer Center BarcelonaInternational University of Catalunya (UIC)BarcelonaSpain
| | - Maribel Ramis
- Ace Alzheimer Center BarcelonaInternational University of Catalunya (UIC)BarcelonaSpain
| | - Joel Simrén
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
| | - Johanna Nilsson
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
| | - Juan Lantero‐Rodriguez
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
| | - Adelina Orellana
- Ace Alzheimer Center BarcelonaInternational University of Catalunya (UIC)BarcelonaSpain
| | | | - Xavier Morató
- Networking Research Center on Neurodegenerative Diseases (CIBERNED)Instituto de Salud Carlos IIIMadridSpain
- Ace Alzheimer Center BarcelonaInternational University of Catalunya (UIC)BarcelonaSpain
| | - Nicholas J. Ashton
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & NeuroscienceKing's College LondonLondonUK
- Centre for Age‐Related MedicineStavanger University HospitalStavangerNorway
| | - Laia Montoliu‐Gaya
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Shagreens Academy at the University of GothenburgMölndalSweden
| |
Collapse
|
80
|
Kudo K, Ranasinghe KG, Morise H, Syed F, Sekihara K, Rankin KP, Miller BL, Kramer JH, Rabinovici GD, Vossel K, Kirsch HE, Nagarajan SS. Neurophysiological trajectories in Alzheimer's disease progression. eLife 2024; 12:RP91044. [PMID: 38546337 PMCID: PMC10977971 DOI: 10.7554/elife.91044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/01/2024] Open
Abstract
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.
Collapse
Affiliation(s)
- Kiwamu Kudo
- Biomagnetic Imaging Laboratory, Department of Radiology and Biomedical Imaging, University of California, San FranciscoSan FranciscoUnited States
- Medical Imaging Business Center, Ricoh Company LtdKanazawaJapan
| | - Kamalini G Ranasinghe
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
| | - Hirofumi Morise
- Biomagnetic Imaging Laboratory, Department of Radiology and Biomedical Imaging, University of California, San FranciscoSan FranciscoUnited States
- Medical Imaging Business Center, Ricoh Company LtdKanazawaJapan
| | - Faatimah Syed
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
| | | | - Katherine P Rankin
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
| | - Bruce L Miller
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
| | - Joel H Kramer
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
| | - Gil D Rabinovici
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
- Department of Radiology and Biomedical Imaging, University of California, San FranciscoSan FranciscoUnited States
| | - Keith Vossel
- Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San FranciscoSan FranciscoUnited States
- Mary S. Easton Center for Alzheimer’s Research and Care, Department of Neurology, David Geffen School of Medicine, University of California, Los AngelesLos AngelesUnited States
| | - Heidi E Kirsch
- Biomagnetic Imaging Laboratory, Department of Radiology and Biomedical Imaging, University of California, San FranciscoSan FranciscoUnited States
| | - Srikantan S Nagarajan
- Biomagnetic Imaging Laboratory, Department of Radiology and Biomedical Imaging, University of California, San FranciscoSan FranciscoUnited States
| |
Collapse
|
81
|
Petersen SI, Okolicsanyi RK, Haupt LM. Exploring Heparan Sulfate Proteoglycans as Mediators of Human Mesenchymal Stem Cell Neurogenesis. Cell Mol Neurobiol 2024; 44:30. [PMID: 38546765 PMCID: PMC10978659 DOI: 10.1007/s10571-024-01463-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 02/19/2024] [Indexed: 04/01/2024]
Abstract
Alzheimer's disease (AD) and traumatic brain injury (TBI) are major public health issues worldwide, with over 38 million people living with AD and approximately 48 million people (27-69 million) experiencing TBI annually. Neurodegenerative conditions are characterised by the accumulation of neurotoxic amyloid beta (Aβ) and microtubule-associated protein Tau (Tau) with current treatments focused on managing symptoms rather than addressing the underlying cause. Heparan sulfate proteoglycans (HSPGs) are a diverse family of macromolecules that interact with various proteins and ligands and promote neurogenesis, a process where new neural cells are formed from stem cells. The syndecan (SDC) and glypican (GPC) HSPGs have been implicated in AD pathogenesis, acting as drivers of disease, as well as potential therapeutic targets. Human mesenchymal stem cells (hMSCs) provide an attractive therapeutic option for studying and potentially treating neurodegenerative diseases due to their relative ease of isolation and subsequent extensive in vitro expansive potential. Understanding how HSPGs regulate protein aggregation, a key feature of neurodegenerative disorders, is essential to unravelling the underlying disease processes of AD and TBI, as well as any link between these two neurological disorders. Further research may validate HSPG, specifically SDCs or GPCs, use as neurodegenerative disease targets, either via driving hMSC stem cell therapy or direct targeting.
Collapse
Affiliation(s)
- Sofia I Petersen
- Stem Cell and Neurogenesis Group, School of Biomedical Sciences, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, QLD, 4059, Australia
| | - Rachel K Okolicsanyi
- Stem Cell and Neurogenesis Group, School of Biomedical Sciences, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, QLD, 4059, Australia
- Max Planck Queensland Centre for the Materials Sciences of Extracellular Matrices, Kelvin Grove, Australia
| | - Larisa M Haupt
- Stem Cell and Neurogenesis Group, School of Biomedical Sciences, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, QLD, 4059, Australia.
- ARC Training Centre for Cell and Tissue Engineering Technologies, Queensland University of Technology (QUT), Kelvin Grove, Australia.
- Max Planck Queensland Centre for the Materials Sciences of Extracellular Matrices, Kelvin Grove, Australia.
| |
Collapse
|
82
|
Hönig M, Altomare D, Caprioglio C, Collij L, Barkhof F, Van Berckel B, Scheltens P, Farrar G, Battle MR, Theis H, Giehl K, Bischof GN, Garibotto V, Molinuevo JLL, Grau-Rivera O, Delrieu J, Payoux P, Demonet JF, Nordberg AK, Savitcheva I, Walker Z, Edison P, Stephens AW, Gismondi R, Jessen F, Buckley CJ, Gispert JD, Frisoni GB, Drzezga A. Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease. Neurology 2024; 102:e208053. [PMID: 38377442 PMCID: PMC11033981 DOI: 10.1212/wnl.0000000000208053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 10/13/2023] [Indexed: 02/22/2024] Open
Abstract
OBJECTIVES Higher-educated patients with Alzheimer disease (AD) can harbor greater neuropathologic burden than those with less education despite similar symptom severity. In this study, we assessed whether this observation is also present in potential preclinical AD stages, namely in individuals with subjective cognitive decline and clinical features increasing AD likelihood (SCD+). METHODS Amyloid-PET information ([18F]Flutemetamol or [18F]Florbetaben) of individuals with SCD+, mild cognitive impairment (MCI), and AD were retrieved from the AMYPAD-DPMS cohort, a multicenter randomized controlled study. Group classification was based on the recommendations by the SCD-I and NIA-AA working groups. Amyloid PET images were acquired within 8 months after initial screening and processed with AMYPYPE. Amyloid load was based on global Centiloid (CL) values. Educational level was indexed by formal schooling and subsequent higher education in years. Using linear regression analysis, the main effect of education on CL values was tested across the entire cohort, followed by the assessment of an education-by-diagnostic-group interaction (covariates: age, sex, and recruiting memory clinic). To account for influences of non-AD pathology and comorbidities concerning the tested amyloid-education association, we compared white matter hyperintensity (WMH) severity, cardiovascular events, depression, and anxiety history between lower-educated and higher-educated groups within each diagnostic category using the Fisher exact test or χ2 test. Education groups were defined using a median split on education (Md = 13 years) in a subsample of the initial cohort, for whom this information was available. RESULTS Across the cohort of 212 individuals with SCD+ (M(Age) = 69.17 years, F 42.45%), 258 individuals with MCI (M(Age) = 72.93, F 43.80%), and 195 individuals with dementia (M(Age) = 74.07, F 48.72%), no main effect of education (ß = 0.52, 95% CI -0.30 to 1.58), but a significant education-by-group interaction on CL values, was found (p = 0.024) using linear regression modeling. This interaction was driven by a negative association of education and CL values in the SCD+ group (ß = -0.11, 95% CI -4.85 to -0.21) and a positive association in the MCI group (ß = 0.15, 95% CI 0.79-5.22). No education-dependent differences in terms of WMH severity and comorbidities were found in the subsample (100 cases with SCD+, 97 cases with MCI, 72 cases with dementia). DISCUSSION Education may represent a factor oppositely modulating subjective awareness in preclinical stages and objective severity of ongoing neuropathologic processes in clinical stages.
Collapse
Affiliation(s)
- Merle Hönig
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Daniele Altomare
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Camilla Caprioglio
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Lyduine Collij
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Frederik Barkhof
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Bart Van Berckel
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Philip Scheltens
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Gill Farrar
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Mark R Battle
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Hendrik Theis
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Kathrin Giehl
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Gerard N Bischof
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Valentina Garibotto
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - José Luis L Molinuevo
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Oriol Grau-Rivera
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Julien Delrieu
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Pierre Payoux
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Jean Francois Demonet
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Agneta K Nordberg
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Irina Savitcheva
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Zuzana Walker
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Paul Edison
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Andrew W Stephens
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Rossella Gismondi
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Frank Jessen
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Christopher J Buckley
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Juan Domingo Gispert
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Giovanni B Frisoni
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| | - Alexander Drzezga
- From the Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne (M.H., H.T., K.G., G.N.B., A.D.), University of Cologne; Institute of Neuroscience and Medicine (INM-2) (M.H., K.G., A.D.), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany; Neurology Unit (D.A.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE) (D.A.), University of Geneva; Geneva Memory Center (D.A., C.C., G.B.F.), Geneva University Hospitals, Switzerland; Amsterdam UMC (L.C., F.B., B.V.B., P.S.), Location VUmc, Radiology; Amsterdam Neuroscience (L.C., F.B., B.V.B., P.S.), Brain Imaging, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing (F.B.), University College London; GE Healthcare (G.F., M.R.B., C.J.B.), Pharmaceutical Diagnostics, Amersham, United Kingdom; Department of Neurology (H.T.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Division of Nuclear Medicine and Molecular Imaging (V.G.), Diagnostic Department, University Hospitals of Geneva; Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTLab) (V.G.), Faculty of Medicine, Department of Radiology, University of Geneva; Center for Biomedical Imaging (CIBM) (V.G.), Geneva, Switzerland; Barcelonaβeta Brain Research Center (BBRC) (J.L.L.M., O.G.-R., J.D.G.), Pasqual Maragall Foundation, Barcelona, Spain; Gérontopôle (J.D., P.P., J.F.D.), Department of Geriatrics, Toulouse University Hospital; Maintain Aging Research Team (J.D.), CERPOP, Inserm, Université Paul Sabatier, Toulouse; ToNIC (P.P.), Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Center for Alzheimer Research (A.K.N.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Inflammation and Aging (A.K.N.), Karolinska University Hospital, Stockholm; Medical Radiation Physics and Nuclear Medicine (I.S.), Karolinska University Hospital, Sweden; Division of Psychiatry (Z.W.), University College London, London and Essex Partnership University NHS Foundation Trust; Department of Brain Sciences (P.E.), Imperial College London, United Kingdom; Life Molecular Imaging (A.W.S., R.G.), Berlin; Department of Psychiatry (F.J.), Faculty of Medicine and University Hospital Cologne, University of Cologne; and German Center for Neurodegenerative Diseases (DZNE) (F.J., A.D.), Bonn-Cologne, Germany
| |
Collapse
|
83
|
Ackley S, Calmasini C, Bouteloup V, Hill-Jarrett TG, Swinnerton KN, Chêne G, Dufouil C, Glymour MM. Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort. Neurology 2024; 102:e208054. [PMID: 38412412 DOI: 10.1212/wnl.0000000000208054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 10/16/2023] [Indexed: 02/29/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Global amyloid-PET is associated with cognition and cognitive decline, but most research on this association does not account for past cognitive information. We assessed the prognostic benefit of amyloid-PET measures for future cognition when prior cognitive assessments are available, evaluating the added value of amyloid measures beyond information on multiple past cognitive assessments. METHODS The French MEMENTO cohort (a cohort of outpatients from French research memory centers to improve knowledge on Alzheimer disease and related disorders) includes older outpatients with incipient cognitive changes, but no dementia diagnosis at inclusion. Global amyloid burden was assessed using positron emission tomography (amyloid-PET) for a subset of participants; semiannual cognitive testing was subsequently performed. We predicted mini-mental state examination (MMSE) scores using demographic characteristics (age, sex, marital status, and education) alone or in combination with information on prior cognitive measures. The added value of amyloid burden as a predictor in these models was evaluated with percent reduction of the mean squared error (MSE). All models were conducted separately for evaluating the added value of dichotomous amyloid positivity status compared with a continuous amyloid-standardized uptake-value ratio. RESULTS Our analytic sample comprised 510 individuals who underwent amyloid-PET scans with at least 4 MMSE assessments. The mean age at the PET scan was 71.6 (standard deviation 7.4) years; 60.7% were female. The median follow-up was 4.6 years (interquartile range: 0.9 years). Adding amyloid burden when adjusting for only demographic characteristics reduced the MSE of predictions by 5.08% (95% CI 0.97%-10.86%) and 12.64% (95% CI 3.35%-25.28%) for binary and continuous amyloid, respectively. If the model included 1 past MMSE measure, the MSE improvement was 3.51% (95% CI 1.01%-7.28%) when adding binary amyloid and 8.83% (95% CI 2.63%-16.37%) when adding continuous amyloid. Improvements in model fit were smaller with the addition of amyloid burden when more than 1 past cognitive assessment was included. For all models incorporating past cognitive assessments, differences in predictions amounted to a fraction of 1 MMSE point on average. DISCUSSION In a clinical setting, global amyloid burden did not appreciably improve cognitive predictions when past cognitive assessments were available. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov Identifier: NCT02164643.
Collapse
Affiliation(s)
- Sarah Ackley
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - Camilla Calmasini
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - Vincent Bouteloup
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - Tanisha G Hill-Jarrett
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - Kaitlin N Swinnerton
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - Geneviève Chêne
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - Carole Dufouil
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| | - M M Glymour
- From the Department of Epidemiology (S.A., M.M.G.), Boston University, MA; Department of Epidemiology and Biostatistics (C.C., K.N.S.), University of California, San Francisco; University Bordeaux (V.B., G.C., C.D.), Inserm, UMR 1219; Pole de sante publique Centre Hospitalier Universitaire (CHU) de Bordeaux (V.B., G.C., C.D.), France; and Memory & Aging Center (T.G.H.-J.), University of California, San Francisco
| |
Collapse
|
84
|
Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, An Y, Smirnov D, Kulczyńska-Przybik A, Varma VR, Ashton NJ, Montoliu-Gaya L, Camporesi E, Winkel I, Paradowski B, Moghekar A, Troncoso JC, Lashley T, Brinkmalm G, Resnick SM, Mroczko B, Kvartsberg H, Gregorič Kramberger M, Hanrieder J, Čučnik S, Harrison P, Zetterberg H, Lewczuk P, Thambisetty M, Rot U, Galasko D, Blennow K, Karikari TK. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology. Nat Commun 2024; 15:2615. [PMID: 38521766 PMCID: PMC10960791 DOI: 10.1038/s41467-024-46876-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 03/04/2024] [Indexed: 03/25/2024] Open
Abstract
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212. In five cohorts (n = 388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations. The diagnostic accuracy and fold changes of plasma p-tau212 were similar to those for p-tau217 but higher than p-tau181 and p-tau231. Immunofluorescent staining of brain tissue slices showed prominent p-tau212 reactivity in neurofibrillary tangles that co-localized with p-tau217 and p-tau202/205. These findings support plasma p-tau212 as a peripherally accessible biomarker of AD pathophysiology.
Collapse
Grants
- R01 AG075336 NIA NIH HHS
- R01 AG078796 NIA NIH HHS
- R01 AG083874 NIA NIH HHS
- R01 AG072641 NIA NIH HHS
- R01 AG068398 NIA NIH HHS
- R21 AG078538 NIA NIH HHS
- R01 MH108509 NIMH NIH HHS
- RF1 AG025516 NIA NIH HHS
- P30 AG066468 NIA NIH HHS
- R01 AG073267 NIA NIH HHS
- P01 AG025204 NIA NIH HHS
- #AARF-21-850325 Alzheimer's Association
- R01 MH121619 NIMH NIH HHS
- R37 AG023651 NIA NIH HHS
- R21 AG080705 NIA NIH HHS
- U24 AG082930 NIA NIH HHS
- RF1 AG052525 NIA NIH HHS
- R01 AG053952 NIA NIH HHS
- Demensförbundet (Dementia Association)
- Anna Lisa and Brother Björnsson’s Foundation
- BrightFocus Foundation (BrightFocus)
- Alzheimerfonden
- the Swedish Dementia Foundation, Gun and Bertil Stohnes Foundation, Åhlén-stifelsen, and Gamla Tjänarinnor Foundation.
- Vetenskapsrådet (Swedish Research Council)
- Alzheimer’s Drug Discovery Foundation (ADDF)
- EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
- EU Joint Programme – Neurodegenerative Disease Research (Programi i Përbashkët i BE-së për Kërkimet mbi Sëmundjet Neuro-degjeneruese)
- Swedish State Support for Clinical Research (#ALFGBG-71320), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C) the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Hjärnfonden, Sweden (#FO2022-0270), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003)
- the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01) the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495).
- Alzheimer’s Association
- National Institute of Health (NIH) - (R01 AG083874-01, U24 AG082930-01 1 RF1 AG052525-01A1, 5 P30 AG066468-04, 5 R01 AG053952-05, 3 R01 MH121619-04S1, 5 R37 AG023651-18, 2 RF1 AG025516-12A1, 5 R01 AG073267-02, 2 R01 MH108509-06, 5 R01 AG075336-02, 5 R01 AG072641-02, 2 P01 AG025204-16) the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallströms and Mary-Ann Sjöbloms stiftelsen, and the Emil och Wera Cornells stiftelsen.
Collapse
Affiliation(s)
- Przemysław R Kac
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.
| | - Fernando González-Ortiz
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden
| | - Andreja Emeršič
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - Maciej Dulewicz
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
| | - Srinivas Koutarapu
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
| | | | - Yang An
- Brain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA
| | - Denis Smirnov
- Department of Neurosciences, University of California, San Diego, CA, 92161, USA
| | | | - Vijay R Varma
- Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA
| | - Nicholas J Ashton
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Department of Old Age Psychiatry, King's College London, London, SE5 8AF, UK
- Centre for Age-Related Medicine, Stavanger University Hospital, 4011, Stavanger, Norway
- South London & Maudsley NHS Foundation, NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia, SE5 8AF, London, UK
| | - Laia Montoliu-Gaya
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
| | - Elena Camporesi
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
| | - Izabela Winkel
- Dementia Disorders Center, Medical University of Wrocław, 59-330, Ścinawa, Poland
| | - Bogusław Paradowski
- Department of Neurology, Medical University of Wrocław, 50-556, Wrocław, Poland
| | - Abhay Moghekar
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA
| | - Juan C Troncoso
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA
- Department of Pathology, John Hopkins University School of Medicine, Baltimore, MD, 21287, USA
| | - Tammaryn Lashley
- Department of Neurodegenerative diseases, UCL Queen Square Institute of Neurology, WC1N 1PJ, London, UK
| | - Gunnar Brinkmalm
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
| | - Susan M Resnick
- Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA
| | - Barbara Mroczko
- Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, 15-269, Poland
| | - Hlin Kvartsberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden
| | - Milica Gregorič Kramberger
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, 141 52, Huddinge, Sweden
| | - Jörg Hanrieder
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1E 6BT, UK
| | - Saša Čučnik
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
- Department of Rheumatology, University Medical Center Ljubljana, Ljubljana, Slovenia
| | | | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden
- Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1E 6BT, UK
- UK Dementia Research Institute, University College London, London, WC1E 6BT, UK
- Hong Kong Center for Neurodegenerative Diseases, HKCeND, Hong Kong, 1512-1518, China
- School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA
| | - Piotr Lewczuk
- Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok, 15-269, Poland
- Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
| | - Madhav Thambisetty
- Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, 21224, USA
| | - Uroš Rot
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia
- Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Douglas Galasko
- Department of Neurosciences, University of California, San Diego, CA, 92161, USA
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden
| | - Thomas K Karikari
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| |
Collapse
|
85
|
Mitsuishi Y, Nakano M, Kojima H, Okabe T, Nishimura M. Reduction of Amyloid-β Production without Inhibiting Secretase Activity by MS-275. ACS Chem Neurosci 2024; 15:1234-1241. [PMID: 38416107 DOI: 10.1021/acschemneuro.3c00848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/29/2024] Open
Abstract
Brain amyloid-β (Aβ) governs the pathogenic process of Alzheimer's disease. Clinical trials to assess the disease-modifying effects of inhibitors or modulators of β- and γ-secretases have not shown clinical benefit and can cause serious adverse events. Previously, we found that the interleukin-like epithelial-to-mesenchymal transition inducer (ILEI, also known as FAM3C) negatively regulates the Aβ production through a decrease in Aβ immediate precursor, without the inhibition of β- and γ-secretase activity. Herein, we found that MS-275, a benzamide derivative that is known to inhibit histone deacetylases (HDACs), exhibits ILEI-like activity to reduce Aβ production independent of HDAC inhibition. Chronic MS-275 treatment decreased Aβ deposition in the cerebral cortex and hippocampus in an Alzheimer's disease mouse model. Overall, our results indicate that MS-275 is a potential therapeutic candidate for efficiently reducing brain Aβ accumulation.
Collapse
Affiliation(s)
- Yachiyo Mitsuishi
- Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga 520-2192, Japan
| | - Masaki Nakano
- Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga 520-2192, Japan
| | - Hirotatsu Kojima
- Drug Discovery Institute, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
| | - Takayoshi Okabe
- Drug Discovery Institute, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
| | - Masaki Nishimura
- Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga 520-2192, Japan
- Department of Neurology, Yoka Municipal Hospital, Hyogo 667-0051, Japan
| |
Collapse
|
86
|
Kim RT, Zhou L, Li Y, Krieger AC, Nordvig AS, Butler T, de Leon MJ, Chiang GC. Impaired sleep is associated with tau deposition on 18F-flortaucipir PET and accelerated cognitive decline, accounting for medications that affect sleep. J Neurol Sci 2024; 458:122927. [PMID: 38341949 PMCID: PMC10947806 DOI: 10.1016/j.jns.2024.122927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 01/06/2024] [Accepted: 02/06/2024] [Indexed: 02/13/2024]
Abstract
BACKGROUND Impaired sleep is commonly associated with Alzheimer's disease (AD), although the underlying mechanisms remain unclear. Furthermore, the moderating effects of sleep-affecting medications, which have been linked to AD pathology, are incompletely characterized. Using data from the Alzheimer's Disease Neuroimaging Initiative, we investigated whether a medical history of impaired sleep, informant-reported nighttime behaviors, and sleep-affecting medications are associated with beta-amyloid and tau deposition on PET and cognitive change, cross-sectionally and longitudinally. METHODS We included 964 subjects with 18F-florbetapir PET scans. Measures of sleep impairment and medication use were obtained from medical histories and the Neuropsychiatric Inventory Questionnaire. Multivariate models, adjusted for covariates, were used to assess associations among sleep-related features, beta-amyloid and tau, and cognition. Cortical tau deposition, categorized by Braak stage, was assessed using the standardized uptake value peak alignment (SUVP) method on 18F-flortaucipir PET. RESULTS Medical history of sleep impairment was associated with greater baseline tau in the meta-temporal, Braak 1, and Braak 4 regions (p = 0.04, p < 0.001, p = 0.025, respectively). Abnormal nighttime behaviors were also associated with greater baseline tau in the meta-temporal region (p = 0.024), and greater cognitive impairment, cross-sectionally (p = 0.007) and longitudinally (p < 0.001). Impaired sleep was not associated with baseline beta-amyloid (p > 0.05). Short-term use of selective serotonin reuptake inhibitors and benzodiazepines slightly weakened the sleep-tau relationship. CONCLUSIONS Sleep impairment was associated with tauopathy and cognitive decline, which could be linked to increased tau secretion from neuronal hyperactivity. Clinically, our results help identify high-risk individuals who could benefit from sleep-related interventions aimed to delay cognitive decline and AD.
Collapse
Affiliation(s)
- Ryan T Kim
- From the Department of Stem Cell and Regenerative Biology, Harvard University, Bauer-Sherman Fairchild Complex 7 Divinity Avenue, Cambridge, MA 02138, United States of America.
| | - Liangdong Zhou
- From the Department of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 407 E 61(st) Street, New York, NY 10065, United States of America.
| | - Yi Li
- From the Department of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 407 E 61(st) Street, New York, NY 10065, United States of America.
| | - Ana C Krieger
- From the Departments of Medicine and Neurology, Division of Sleep Neurology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 425 E 61st St., 5th Floor, New York, NY 10065, United States of America.
| | - Anna S Nordvig
- From the Department of Neurology, Alzheimer's Disease and Memory Disorders Program, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 428 East 72(nd) Street Suite 500, New York, NY 10021, United States of America.
| | - Tracy Butler
- From the Department of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 407 E 61(st) Street, New York, NY 10065, United States of America.
| | - Mony J de Leon
- From the Department of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 407 E 61(st) Street, New York, NY 10065, United States of America.
| | - Gloria C Chiang
- From the Department of Radiology, Brain Health Imaging Institute, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 407 E 61(st) Street, New York, NY 10065, United States of America; From the Department of Radiology, Division of Neuroradiology, Weill Cornell Medicine, NewYork-Presbyterian Hospital, 525 East 68th Street, Starr Pavilion, Box 141, New York, NY 10065, United States of America.
| |
Collapse
|
87
|
Brum WS, Cullen NC, Therriault J, Janelidze S, Rahmouni N, Stevenson J, Servaes S, Benedet AL, Zimmer ER, Stomrud E, Palmqvist S, Zetterberg H, Frisoni GB, Ashton NJ, Blennow K, Mattsson-Carlgren N, Rosa-Neto P, Hansson O. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat Commun 2024; 15:2311. [PMID: 38486040 PMCID: PMC10940585 DOI: 10.1038/s41467-024-46603-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 03/04/2024] [Indexed: 03/18/2024] Open
Abstract
Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer's disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in memory clinic patients with subjective cognitive decline, mild cognitive impairment or dementia, in the Swedish BioFINDER-2 study (n = 548) and in the TRIAD study (n = 179). For each plasma biomarker, cutoffs were determined for 90%, 95%, or 97.5% sensitivity to detect tau-PET-positivity. We calculated the percentage of patients below the cutoffs (who would not undergo tau-PET; "saved scans") and the tau-PET-positivity rate among participants above the cutoffs (who would undergo tau-PET; "positive predictive value"). Generally, plasma pTau217 performed best. At the 95% sensitivity cutoff in both cohorts, pTau217 resulted in avoiding nearly half tau-PET scans, with a tau-PET-positivity rate among those who would be referred for a scan around 70%. And although tau-PET was strongly associated with subsequent cognitive decline, in BioFINDER-2 it predicted cognitive decline only among individuals above the referral cutoff on plasma pTau217, supporting that this workflow could reduce prognostically uninformative tau-PET scans. In conclusion, plasma pTau217 may guide selection of patients for tau-PET, when accurate prognostic information is of clinical value.
Collapse
Affiliation(s)
- Wagner S Brum
- Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| | - Nicholas C Cullen
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
| | - Joseph Therriault
- McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, QC, Canada
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Quebec, QC, Canada
| | - Shorena Janelidze
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden
| | - Nesrine Rahmouni
- McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, QC, Canada
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Quebec, QC, Canada
| | - Jenna Stevenson
- McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, QC, Canada
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Quebec, QC, Canada
| | - Stijn Servaes
- McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, QC, Canada
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Quebec, QC, Canada
| | - Andrea L Benedet
- Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
| | - Eduardo R Zimmer
- Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
- McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, QC, Canada
- Department of Pharmacology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
- Graduate Program in Biological Sciences: Pharmacology, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| | - Erik Stomrud
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden
- Memory Clinic, Skåne University Hospital, Lund, Sweden
| | - Sebastian Palmqvist
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden
- Memory Clinic, Skåne University Hospital, Lund, Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
- UK Dementia Research Institute at UCL, London, United Kingdom
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
- Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
| | - Giovanni B Frisoni
- Memory Center, Geneva University and University Hospital, Geneva, Switzerland
| | - Nicholas J Ashton
- Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- King's College London, Institute of Psychiatry, Psychology and Neuroscience Maurice Wohl Institute Clinical Neuroscience Institute, London, UK
- NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK
- Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Niklas Mattsson-Carlgren
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden
- Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
- Department of Neurology, Skåne University Hospital, Lund, Sweden
| | - Pedro Rosa-Neto
- McGill Centre for Studies in Aging, McGill University, Verdun, Quebec, QC, Canada
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Quebec, QC, Canada
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
| |
Collapse
|
88
|
Zhang Y, Xue L, Zhang S, Yang J, Zhang Q, Wang M, Wang L, Zhang M, Jiang J, Li Y. A novel spatiotemporal graph convolutional network framework for functional connectivity biomarkers identification of Alzheimer's disease. Alzheimers Res Ther 2024; 16:60. [PMID: 38481280 PMCID: PMC10938710 DOI: 10.1186/s13195-024-01425-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 03/03/2024] [Indexed: 03/17/2024]
Abstract
BACKGROUND Functional connectivity (FC) biomarkers play a crucial role in the early diagnosis and mechanistic study of Alzheimer's disease (AD). However, the identification of effective FC biomarkers remains challenging. In this study, we introduce a novel approach, the spatiotemporal graph convolutional network (ST-GCN) combined with the gradient-based class activation mapping (Grad-CAM) model (STGC-GCAM), to effectively identify FC biomarkers for AD. METHODS This multi-center cross-racial retrospective study involved 2,272 participants, including 1,105 cognitively normal (CN) subjects, 790 mild cognitive impairment (MCI) individuals, and 377 AD patients. All participants underwent functional magnetic resonance imaging (fMRI) and T1-weighted MRI scans. In this study, firstly, we optimized the STGC-GCAM model to enhance classification accuracy. Secondly, we identified novel AD-associated biomarkers using the optimized model. Thirdly, we validated the imaging biomarkers using Kaplan-Meier analysis. Lastly, we performed correlation analysis and causal mediation analysis to confirm the physiological significance of the identified biomarkers. RESULTS The STGC-GCAM model demonstrated great classification performance (The average area under the curve (AUC) values for different categories were: CN vs MCI = 0.98, CN vs AD = 0.95, MCI vs AD = 0.96, stable MCI vs progressive MCI = 0.79). Notably, the model identified specific brain regions, including the sensorimotor network (SMN), visual network (VN), and default mode network (DMN), as key differentiators between patients and CN individuals. These brain regions exhibited significant associations with the severity of cognitive impairment (p < 0.05). Moreover, the topological features of important brain regions demonstrated excellent predictive capability for the conversion from MCI to AD (Hazard ratio = 3.885, p < 0.001). Additionally, our findings revealed that the topological features of these brain regions mediated the impact of amyloid beta (Aβ) deposition (bootstrapped average causal mediation effect: β = -0.01 [-0.025, 0.00], p < 0.001) and brain glucose metabolism (bootstrapped average causal mediation effect: β = -0.02 [-0.04, -0.001], p < 0.001) on cognitive status. CONCLUSIONS This study presents the STGC-GCAM framework, which identifies FC biomarkers using a large multi-site fMRI dataset.
Collapse
Affiliation(s)
- Ying Zhang
- School of Communication and Information Engineering, Shanghai University, Shanghai, 200444, China
| | - Le Xue
- Department of Nuclear Medicine, the Second Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China
| | - Shuoyan Zhang
- School of Communication and Information Engineering, Shanghai University, Shanghai, 200444, China
| | - Jiacheng Yang
- Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China
| | - Qi Zhang
- School of Communication and Information Engineering, Shanghai University, Shanghai, 200444, China
| | - Min Wang
- Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China
| | - Luyao Wang
- Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China
| | - Mingkai Zhang
- Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
| | - Jiehui Jiang
- Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
| | - Yunxia Li
- Department of Neurology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Shanghai, 201399, Pudong, China.
| |
Collapse
|
89
|
Graham N, Zimmerman K, Heslegrave AJ, Keshavan A, Moro F, Abed-Maillard S, Bernini A, Dunet V, Garbero E, Nattino G, Chieregato A, Fainardi E, Baciu C, Gradisek P, Magnoni S, Oddo M, Bertolini G, Schott JM, Zetterberg H, Sharp D. Alzheimer's disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI. J Neurol Neurosurg Psychiatry 2024; 95:356-359. [PMID: 37833041 PMCID: PMC10958285 DOI: 10.1136/jnnp-2023-331854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 09/19/2023] [Indexed: 10/15/2023]
Abstract
BACKGROUND Traumatic brain injury (TBI) is associated with the tauopathies Alzheimer's disease and chronic traumatic encephalopathy. Advanced immunoassays show significant elevations in plasma total tau (t-tau) early post-TBI, but concentrations subsequently normalise rapidly. Tau phosphorylated at serine-181 (p-tau181) is a well-validated Alzheimer's disease marker that could potentially seed progressive neurodegeneration. We tested whether post-traumatic p-tau181 concentrations are elevated and relate to progressive brain atrophy. METHODS Plasma p-tau181 and other post-traumatic biomarkers, including total-tau (t-tau), neurofilament light (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), were assessed after moderate-to-severe TBI in the BIO-AX-TBI cohort (first sample mean 2.7 days, second sample within 10 days, then 6 weeks, 6 months and 12 months, n=42). Brain atrophy rates were assessed in aligned serial MRI (n=40). Concentrations were compared patients with and without Alzheimer's disease, with healthy controls. RESULTS Plasma p-tau181 concentrations were significantly raised in patients with Alzheimer's disease but not after TBI, where concentrations were non-elevated, and remained stable over one year. P-tau181 after TBI was not predictive of brain atrophy rates in either grey or white matter. In contrast, substantial trauma-associated elevations in t-tau, NfL, GFAP and UCH-L1 were seen, with concentrations of NfL and t-tau predictive of brain atrophy rates. CONCLUSIONS Plasma p-tau181 is not significantly elevated during the first year after moderate-to-severe TBI and levels do not relate to neuroimaging measures of neurodegeneration.
Collapse
Affiliation(s)
- Neil Graham
- Brain Sciences, Imperial College London, London, UK
- UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK
| | - Karl Zimmerman
- Brain Sciences, Imperial College London, London, UK
- UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK
| | | | - Ashvini Keshavan
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
| | - Federico Moro
- Laboratory of Acute Brain Injury and Neuroprotection, Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
- Dipartimento di Anestesia e Rianimazione, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Samia Abed-Maillard
- Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Adriano Bernini
- Department of Clinical Neurosciences, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Vincent Dunet
- Department of Medical Radiology, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Elena Garbero
- Laboratory of Clinical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy
| | - Giovanni Nattino
- Laboratory of Clinical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy
| | - Arturo Chieregato
- Terapia Intensiva ad indirizzo Neurologico & Neurochirurgico, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Enrico Fainardi
- Department of Experimental and Clinical Sciences, Careggi University Hospital and University of Firenze, Florence, Italy
| | - Camelia Baciu
- Terapia Intensiva ad indirizzo Neurologico & Neurochirurgico, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - Primoz Gradisek
- Clinical Department of Anaesthesiology and Intensive Therapy, University Medical Center, Ljubljana, Slovenia
| | - Sandra Magnoni
- Department of Anesthesia and Intensive Care, Santa Chiara Hospital, Trento, Italy
| | - Mauro Oddo
- Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Directorate for Innovation and Clinical Research, CHUV Lausanne University Hospital, Lausanne, Switzerland
| | - Guido Bertolini
- Laboratory of Clinical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy
| | - Jonathan M Schott
- UK Dementia Research Institute, University College London, London, UK
- Dementia Research Centre and Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
| | - Henrik Zetterberg
- UK Dementia Research Institute, University College London, London, UK
- Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
| | - David Sharp
- Brain Sciences, Imperial College London, London, UK
- UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK
| |
Collapse
|
90
|
Yang S, Fan D, Su S, Wang C, Lin Y, Liang M. Effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) on cognitive impairment and serum levels of Aβ 1-42, tau, P-tau in patients with mild to moderate Alzheimer's disease. Zhongguo Zhen Jiu 2024; 44:255-260. [PMID: 38467498 DOI: 10.13703/j.0255-2930.20230725-k0002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/13/2024]
Abstract
OBJECTIVES To compare the effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) combined with donepezil hydrochloride tablets and donepezil hydrochloride tablets alone on cognitive impairment in patients with mild to moderate Alzheimer's disease(AD), and to explore the mechanism of pressing moxibustion in the treatment of mild to moderate AD from the serum levels of β-amyloid 1-42 (Aβ1-42), microtubule-associated protein tau and phosphorylated tau (P-tau). METHODS A total of 76 patients with mild to moderate AD were randomly divided into an observation group (38 cases, 4 cases dropped out) and a control group (38 cases, 2 cases dropped out). Patients in the control group were given oral donepezil hydrochloride tablets (5 mg each time, once a day). On the basis of the control group, patients in the observation group were treated with pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4), 5 cones per acupoint, once every other day, three times a week. Both groups were treated for 8 weeks. The scores of mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) were compared between the two groups before treatment, after treatment and after 4 and 12 weeks of treatment completion. The serum levels of Aβ1-42, tau and P-tau were detected before and after treatment in the two groups, and the safety was evaluated. RESULTS At each time point after treatment, the MMSE and MoCA scores of the two groups were higher than those before treatment (P<0.05), and the scores in the observation group were higher than those in the control group (P<0.05). After treatment, the serum levels of Aβ1-42, tau and P-tau in the two groups were lower than those before treatment (P<0.05), and above indexes in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the safety level between the two groups (P>0.05). CONCLUSIONS The short-term and long-term effect of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) combined with donepezil hydrochloride tablets in improving cognitive impairment in mild to moderate AD is better than that of donepezil hydrochloride tablets alone, and can reduce serum levels of Aβ1-42, tau and P-tau, which may be one of the mechanisms of pressing moxibustion to improve cognitive impairment.
Collapse
Affiliation(s)
- Shuquan Yang
- Department of Acupuncture-Moxibustion, Second TCM Hospital of Guangdong Province, Guangzhou 510095, China
| | - Dehui Fan
- Department of Acupuncture-Moxibustion, Second TCM Hospital of Guangdong Province, Guangzhou 510095, China.
| | - Shengxia Su
- Department of Acupuncture-Moxibustion, TCM Hospital of Lianzhou City
| | - Chuanxin Wang
- Department of Acupuncture-Moxibustion, Second TCM Hospital of Guangdong Province, Guangzhou 510095, China
| | - Ying Lin
- Department of Acupuncture-Moxibustion, Second TCM Hospital of Guangdong Province, Guangzhou 510095, China
| | - Manguang Liang
- Department of Acupuncture-Moxibustion, Second TCM Hospital of Guangdong Province, Guangzhou 510095, China
| |
Collapse
|
91
|
Nayak K, Sarkar N, Bauri K, De P. Helical Superstructures from the Hierarchical Self-Assembly of Coil-Coil Block Copolymer Guided by Side Chain Amyloid-β(17-19) LVF Peptide. Biomacromolecules 2024; 25:1978-1988. [PMID: 38345926 DOI: 10.1021/acs.biomac.3c01379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
The rational design of precisely controlled hierarchical chiral nanostructures from synthetic polymers garnered inspiration from sophisticated biological materials. Since chiral peptide motifs induce helix formation in macromolecules, herein we report the synthesis of a novel type of hybrid polymer consisting of a β-sheet forming a LVF [L = leucine, V = valine, and F = phenylalanine] tripeptide pendant polymethacrylate block and a poly[poly(ethylene glycol) methyl ether methacrylate] (PPEGMA) block. The designed block copolymer self-organized into helical superstructures with a left-handed twisting sense, as visualized by field emission scanning electron microscopy, transmission electron microscopy, and atomic force microscopy. This intriguing hierarchical self-assembly is driven by the minimalistic peptide motif that itself has a high propensity to adopt an antiparallel β-sheet conformation. We also report the generation of a diverse array of nanostructures, including spherical micelles, spindle micelles, rod-like micelles, vesicles, helical supramolecular fibers, and helical toroids via self-assembly of the designed block copolymer in tetrahydrofuran/water mixed solvents. To realize the observable helical superstructure, a twisted two-dimensional core-shell tape is proposed as a structure model in which the peptide segments form an antiparallel β-sheet with a polymer shell. The findings contribute to the advancement of a helical polymer or the superhelical self-assembly of polymers, paving the way for diverse applications in materials science and related fields.
Collapse
Affiliation(s)
- Kasturee Nayak
- Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur - 741246, Nadia, West Bengal, India
| | - Niharendra Sarkar
- Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur - 741246, Nadia, West Bengal, India
| | - Kamal Bauri
- Department of Chemistry, Raghunathpur College, Raghunathpur - 723133, Purulia, West Bengal, India
| | - Priyadarsi De
- Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur - 741246, Nadia, West Bengal, India
| |
Collapse
|
92
|
Wang SM, Kang DW, Um YH, Kim S, Lee CU, Scheltens P, Lim HK. Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer's disease spectrum. Alzheimers Res Ther 2024; 16:55. [PMID: 38468313 PMCID: PMC10926587 DOI: 10.1186/s13195-024-01400-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 01/26/2024] [Indexed: 03/13/2024]
Abstract
BACKGROUND Multimer detection system-oligomeric amyloid-β (MDS-OAβ) is a measure of plasma OAβ, which is associated with Alzheimer's disease (AD) pathology. However, the relationship between MDS-OAβ and disease severity of AD is not clear. We aimed to investigate MDS-OAβ levels in different stages of AD and analyze the association between MDS-OAβ and cerebral Aβ deposition, cognitive function, and cortical thickness in subjects within the AD continuum. METHODS In this cross-sectional study, we analyzed a total 126 participants who underwent plasma MDS-OAβ, structural magnetic resonance image of brain, and neurocognitive measures using Korean version of the Consortium to Establish a Registry for Alzheimer's Disease, and cerebral Aβ deposition or amyloid positron emission tomography (A-PET) assessed by [18F] flutemetamol PET. Subjects were divided into 4 groups: N = 39 for normal control (NC), N = 31 for A-PET-negative mild cognitive impairment (MCI) patients, N = 30 for A-PET-positive MCI patients, and N = 22 for AD dementia patients. The severity of cerebral Aβ deposition was expressed as standard uptake value ratio (SUVR). RESULTS Compared to the NC (0.803 ± 0.27), MDS-OAβ level was higher in the A-PET-negative MCI group (0.946 ± 0.137) and highest in the A-PET-positive MCI group (1.07 ± 0.17). MDS-OAβ level in the AD dementia group was higher than in the NC, but it fell to that of the A-PET-negative MCI group level (0.958 ± 0.103). There were negative associations between MDS-OAβ and cognitive function and both global and regional cerebral Aβ deposition (SUVR). Cortical thickness of the left fusiform gyrus showed a negative association with MDS-OAβ when we excluded the AD dementia group. CONCLUSIONS These findings suggest that MDS-OAβ is not only associated with neurocognitive staging, but also with cerebral Aβ burden in patients along the AD continuum.
Collapse
Affiliation(s)
- Sheng-Min Wang
- Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul, 07345, South Korea
| | - Dong Woo Kang
- Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, South Korea
| | - Yoo Hyun Um
- Department of Psychiatry, St. Vincent Hospital, Suwon, Korea, College of Medicine, The Catholic University of Korea, Suwon, 16247, South Korea
| | - Sunghwan Kim
- Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul, 07345, South Korea
| | - Chang Uk Lee
- Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, South Korea
| | - Philip Scheltens
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Boelelaan 1118, Amsterdam, 1081, HZ, Netherlands
- EQT Life Sciences Partners, Amsterdam, 1071, DV, The Netherlands
| | - Hyun Kook Lim
- Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul, 07345, South Korea.
| |
Collapse
|
93
|
Zhong MZ, Peng T, Duarte ML, Wang M, Cai D. Updates on mouse models of Alzheimer's disease. Mol Neurodegener 2024; 19:23. [PMID: 38462606 PMCID: PMC10926682 DOI: 10.1186/s13024-024-00712-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 02/14/2024] [Indexed: 03/12/2024] Open
Abstract
Alzheimer's disease (AD) is the most common neurodegenerative disease in the United States (US). Animal models, specifically mouse models have been developed to better elucidate disease mechanisms and test therapeutic strategies for AD. A large portion of effort in the field was focused on developing transgenic (Tg) mouse models through over-expression of genetic mutations associated with familial AD (FAD) patients. Newer generations of mouse models through knock-in (KI)/knock-out (KO) or CRISPR gene editing technologies, have been developed for both familial and sporadic AD risk genes with the hope to more accurately model proteinopathies without over-expression of human AD genes in mouse brains. In this review, we summarized the phenotypes of a few commonly used as well as newly developed mouse models in translational research laboratories including the presence or absence of key pathological features of AD such as amyloid and tau pathology, synaptic and neuronal degeneration as well as cognitive and behavior deficits. In addition, advantages and limitations of these AD mouse models have been elaborated along with discussions of any sex-specific features. More importantly, the omics data from available AD mouse models have been analyzed to categorize molecular signatures of each model reminiscent of human AD brain changes, with the hope to guide future selection of most suitable models for specific research questions to be addressed in the AD field.
Collapse
Affiliation(s)
- Michael Z Zhong
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
- Department of Biology, College of Arts and Science, Boston University, Boston, MA, 02215, USA
| | - Thomas Peng
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
- Science Research Program, Scarsdale High School, New York, NY, 10583, USA
| | - Mariana Lemos Duarte
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Research & Development, James J Peters VA Medical Center, Bronx, NY, 10468, USA.
| | - Minghui Wang
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
- Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
| | - Dongming Cai
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Research & Development, James J Peters VA Medical Center, Bronx, NY, 10468, USA.
- Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Department of Neurology, N. Bud Grossman Center for Memory Research and Care, The University of Minnesota, Minneapolis, MN, 55455, USA.
- Geriatric Research Education & Clinical Center (GRECC), The Minneapolis VA Health Care System, Minneapolis, MN, 55417, USA.
| |
Collapse
|
94
|
Bigi A, Fani G, Bessi V, Napolitano L, Bagnoli S, Ingannato A, Neri L, Cascella R, Matteini P, Sorbi S, Nacmias B, Cecchi C, Chiti F. Putative novel CSF biomarkers of Alzheimer's disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort. Transl Neurodegener 2024; 13:14. [PMID: 38459525 PMCID: PMC10924410 DOI: 10.1186/s40035-024-00405-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 02/16/2024] [Indexed: 03/10/2024] Open
Affiliation(s)
- Alessandra Bigi
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy
| | - Giulia Fani
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy
| | - Valentina Bessi
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi. Largo Brambilla, 3, 50134, Florence, Italy
| | - Liliana Napolitano
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy
| | - Silvia Bagnoli
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi. Largo Brambilla, 3, 50134, Florence, Italy
| | - Assunta Ingannato
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi. Largo Brambilla, 3, 50134, Florence, Italy
| | - Lorenzo Neri
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy
| | - Roberta Cascella
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy
| | - Paolo Matteini
- Institute of Applied Physics "Nello Carrara", National Research Council, 50019, Sesto Fiorentino, Italy
| | - Sandro Sorbi
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi. Largo Brambilla, 3, 50134, Florence, Italy
- IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
| | - Benedetta Nacmias
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Azienda Ospedaliero-Universitaria Careggi. Largo Brambilla, 3, 50134, Florence, Italy
- IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
| | - Cristina Cecchi
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
| | - Fabrizio Chiti
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Section of Biochemistry, University of Florence, Viale Morgagni 50, 50134, Florence, Italy.
| |
Collapse
|
95
|
Nabizadeh F, Valizadeh P, Fallahi MS. Bile acid profile associated with CSF and PET biomarkers in Alzheimer's disease. Aging Clin Exp Res 2024; 36:62. [PMID: 38451317 PMCID: PMC10920417 DOI: 10.1007/s40520-024-02729-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 02/23/2024] [Indexed: 03/08/2024]
Abstract
BACKGROUND Recent studies have shown that gut microbiota can affect the development of Alzheimer's disease (AD) through various mechanisms. Bile acids (BAs), which are the final byproducts of cholesterol metabolism created through both the human body and gut microbiome, appear to be influenced by gut microbiota and may impact AD pathological characteristics such as the accumulation of tau and amyloid-β. We aimed to investigate the associations between various serum BAs and CSF biomarkers (including Aβ, total tau, and p-tau). Additionally, we sought to examine the longitudinal changes in brain Aβ and tau through PET imaging in relation to BAs profile. METHODS The data of 828 subjects including 491 diagnosed with mild cognitive impairment (MCI), 119 patients diagnosed with AD, and 267 cognitively normal (CN) participants were obtained from ADNI. The baseline and longitudinal [18F] florbetapir and [18F] flortaucipir PET standard uptake value ratios (SUVR) measures were obtained to assess the accumulation of tau and Aβ. Moreover, baseline levels of serum BAs and CSF Aβ1-42, tau, and p-tau were used. RESULTS After FDR correction we observed that five BAs level and relevant calculated ratios were associated with CSF p-tau and tau, three with CSF Aβ1-42. Furthermore, three BAs level and relevant calculated ratios were associated with the tau-PET rate of change, and two with the Aβ rate of change. CONCLUSION The findings from our study suggest a correlation between altered profiles of BAs and CSF and imaging biomarkers associated with AD. These results provide supporting evidence for the link between the gut microbiome and the pathological features of AD.
Collapse
Affiliation(s)
- Fardin Nabizadeh
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
| | - Parya Valizadeh
- School of Medicine, Tehran University of Medical Science, Tehran, Iran
| | | |
Collapse
|
96
|
Sofińska K, Seweryn S, Skirlińska-Nosek K, Barbasz J, Lipiec E. Tip-enhanced Raman spectroscopy reveals the structural rearrangements of tau protein aggregates at the growth phase. Nanoscale 2024; 16:5294-5301. [PMID: 38372161 DOI: 10.1039/d3nr06365h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Tau protein aggregates inside neurons in the course of Alzheimer's disease (AD). Because of the enormous number of people suffering from AD, this disease has become one of the world's major health and social problems. The presence of tau lesions clearly correlates with cognitive impairments in AD patients, thus, tau is the target of potential treatments for AD, next to amyloid-β. The exact mechanism of tau aggregation has not been understood in detail so far; especially little is known about the structural rearrangements of tau aggregates at the growth phase. The research into tau conformation at each step of the aggregation pathway will contribute to the design of effective therapeutic approaches. To follow the secondary structure of individual tau aggregates at the growth phase, we applied tip-enhanced Raman spectroscopy (TERS). The nanospectroscopic approach enabled us to follow the structure of individual aggregates occurring in the subsequent phases of tau aggregation. We applied multivariate data analysis to extract the spectral differences for tau aggregates at different aggregation phases. Moreover, atomic force microscopy (AFM) allowed the tracking of the morphological alterations for species occurring with the progression of tau aggregation.
Collapse
Affiliation(s)
- Kamila Sofińska
- Jagiellonian University, Faculty of Physics, Astronomy and Applied Computer Science, M. Smoluchowski Institute of Physics, Łojasiewicza 11, 30-348 Krakow, Poland.
| | - Sara Seweryn
- Jagiellonian University, Faculty of Physics, Astronomy and Applied Computer Science, M. Smoluchowski Institute of Physics, Łojasiewicza 11, 30-348 Krakow, Poland.
- Jagiellonian University, Doctoral School of Exact and Natural Sciences, Krakow, Poland
| | - Katarzyna Skirlińska-Nosek
- Jagiellonian University, Faculty of Physics, Astronomy and Applied Computer Science, M. Smoluchowski Institute of Physics, Łojasiewicza 11, 30-348 Krakow, Poland.
- Jagiellonian University, Doctoral School of Exact and Natural Sciences, Krakow, Poland
| | - Jakub Barbasz
- Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences, Niezapominajek 8, 30-239 Krakow, Poland
| | - Ewelina Lipiec
- Jagiellonian University, Faculty of Physics, Astronomy and Applied Computer Science, M. Smoluchowski Institute of Physics, Łojasiewicza 11, 30-348 Krakow, Poland.
| |
Collapse
|
97
|
Cai X, Luo Y, Song Y. Palladium nanoballs coupled with smartphone-thermal reader for photothermal lateral flow immunoassay of Aβ 1-40. J Mater Chem B 2024; 12:2610-2617. [PMID: 38372378 DOI: 10.1039/d3tb02641h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2024]
Abstract
Amyloid beta 1-40 (Aβ 1-40) is one of the most abundant substances in the body with the capacity to form insoluble aggregates and is a universal biomarker for the prediction of Alzheimer's disease. Here, a palladium nanoball (PNB)-strip was developed and coupled with a smartphone-thermal reader as an ultrasensitive and cost-effective platform for Aβ 1-40 detection. In this study, PNB was synthesized and introduced into lateral flow strips as an alternative signal source to gold nanoparticles to improve sensitivity because the PNB has a better heat generation ability. Quantitative analysis was performed using a self-developed smartphone-thermal reader, which is portable and cost-effective. The detection limit of the system was determined to be 20 pg mL-1, which fulfils the need for clinical diagnosis at the point-of-care. This work highlights a PNB-strip coupled smartphone-thermal reader for ultrasensitive and cost-effective Aβ 1-40 detection.
Collapse
Affiliation(s)
- Xiaoli Cai
- Academy of Nutrition and Health, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, School of Public Health, Wuhan University of Science and Technology, Wuhan 430065, China.
| | - Yangxing Luo
- Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Yang Song
- NANOGENE LLC, Gainesville, Florida 32611, USA.
| |
Collapse
|
98
|
Wen Q, Wittens MMJ, Engelborghs S, van Herwijnen MHM, Tsamou M, Roggen E, Smeets B, Krauskopf J, Briedé JJ. Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease. ACS Chem Neurosci 2024; 15:1042-1054. [PMID: 38407050 PMCID: PMC10921410 DOI: 10.1021/acschemneuro.3c00740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 02/01/2024] [Accepted: 02/06/2024] [Indexed: 02/27/2024] Open
Abstract
Alzheimer's disease (AD) is the most common cause of dementia. New strategies for the early detection of MCI and sporadic AD are crucial for developing effective treatment options. Current techniques used for diagnosis of AD are invasive and/or expensive, so they are not suitable for population screening. Cerebrospinal fluid (CSF) biomarkers such as amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau181 (P-tau181) levels are core biomarkers for early diagnosis of AD. Several studies have proposed the use of blood-circulating microRNAs (miRNAs) as potential novel early biomarkers for AD. We therefore applied a novel approach to identify blood-circulating miRNAs associated with CSF biomarkers and explored the potential of these miRNAs as biomarkers of AD. In total, 112 subjects consisting of 28 dementia due to AD cases, 63 MCI due to AD cases, and 21 cognitively healthy controls were included. We identified seven Aβ1-42-associated plasma miRNAs, six P-tau181-associated plasma miRNAs, and nine Aβ1-42-associated serum miRNAs. These miRNAs were involved in AD-relevant biological processes, such as PI3K/AKT signaling. Based on this signaling pathway, we constructed an miRNA-gene target network, wherein miR-145-5p has been identified as a hub. Furthermore, we showed that miR-145-5p performs best in the prediction of both AD and MCI. Moreover, miR-145-5p also improved the prediction performance of the mini-mental state examination (MMSE) score. The performance of this miRNA was validated using different datasets including an RT-qPCR dataset from plasma samples of 23 MCI cases and 30 age-matched controls. These findings indicate that blood-circulating miRNAs that are associated with CSF biomarkers levels and specifically plasma miR-145-5p alone or combined with the MMSE score can potentially be used as noninvasive biomarkers for AD or MCI screening in the general population, although studies in other AD cohorts are necessary for further validation.
Collapse
Affiliation(s)
- Qingfeng Wen
- Department
of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
- MHeNS,
School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Mandy Melissa Jane Wittens
- Department
of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, BE-2610 Antwerpen, Belgium
- Neuroprotection
and Neuromodulation (NEUR), Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussel, Belgium
- Department
of Neurology, Universitair Ziekenhuis Brussel
(UZ Brussel), Laarbeeklaan
101, 1090 Brussel, Belgium
| | - Sebastiaan Engelborghs
- Department
of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, BE-2610 Antwerpen, Belgium
- Neuroprotection
and Neuromodulation (NEUR), Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussel, Belgium
- Department
of Neurology, Universitair Ziekenhuis Brussel
(UZ Brussel), Laarbeeklaan
101, 1090 Brussel, Belgium
| | - Marcel H. M. van Herwijnen
- Department
of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Maria Tsamou
- ToxGenSolutions
(TGS), 6229EV Maastricht, The Netherlands
| | - Erwin Roggen
- ToxGenSolutions
(TGS), 6229EV Maastricht, The Netherlands
| | - Bert Smeets
- Department
of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
- MHeNS,
School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Julian Krauskopf
- Department
of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| | - Jacco Jan Briedé
- Department
of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
- MHeNS,
School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
| |
Collapse
|
99
|
Prosswimmer T, Heng A, Daggett V. Mechanistic insights into the role of amyloid-β in innate immunity. Sci Rep 2024; 14:5376. [PMID: 38438446 PMCID: PMC10912764 DOI: 10.1038/s41598-024-55423-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 02/23/2024] [Indexed: 03/06/2024] Open
Abstract
Colocalization of microbial pathogens and the β-amyloid peptide (Aβ) in the brain of Alzheimer's disease (AD) patients suggests that microbial infection may play a role in sporadic AD. Aβ exhibits antimicrobial activity against numerous pathogens, supporting a potential role for Aβ in the innate immune response. While mammalian amyloid is associated with disease, many bacteria form amyloid fibrils to fortify the biofilm that protects the cells from the surrounding environment. In the microbial AD hypothesis, Aβ aggregates in response to infection to combat the pathogen. We hypothesize that this occurs through toxic Aβ oligomers that contain α-sheet structure and form prior to fibrillization. De novo designed α-sheet peptides specifically bind to the α-sheet structure present in the oligomers of both bacterial and mammalian amyloidogenic proteins to neutralize toxicity and inhibit aggregation. Here, we measure the effect of E. coli on Aβ, including upregulation, aggregation, and toxicity. Additionally, we determined the effect of Aβ structure on E. coli amyloid fibrils, or curli comprised of the CsgA protein, and biofilm formation. We found that curli formation by E. coli increased Aβ oligomer production, and Aβ oligomers inhibited curli biogenesis and reduced biofilm cell density. Further, curli and biofilm inhibition by Aβ oligomers increased E. coli susceptibility to gentamicin. Toxic oligomers of Aβ and CsgA interact via α-sheet interactions, neutralizing their toxicity. These results suggest that exposure to toxic oligomers formed by microbial pathogens triggers Aβ oligomer upregulation and aggregation to combat infection via selective interactions between α-sheet oligomers to neutralize toxicity of both species with subsequent inhibition of fibrillization.
Collapse
Affiliation(s)
- Tatum Prosswimmer
- Molecular Engineering Program, University of Washington, Seattle, WA, 98195-5610, USA
| | - Anthony Heng
- Department of Neuroscience, University of Washington, Seattle, WA, 98195-5610, USA
- Department of Biochemistry, University of Washington, Seattle, WA, 98195-5610, USA
| | - Valerie Daggett
- Molecular Engineering Program, University of Washington, Seattle, WA, 98195-5610, USA.
- Department of Biochemistry, University of Washington, Seattle, WA, 98195-5610, USA.
- Department of Bioengineering, University of Washington, Seattle, WA, 98195-5610, USA.
| |
Collapse
|
100
|
Nabizadeh F, Zafari R. Progranulin and neuropathological features of Alzheimer's disease: longitudinal study. Aging Clin Exp Res 2024; 36:55. [PMID: 38441695 PMCID: PMC10914850 DOI: 10.1007/s40520-024-02715-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 01/26/2024] [Indexed: 03/07/2024]
Abstract
BACKGROUND Progranulin is an anti-inflammatory protein that plays an essential role in the synapse function and the maintenance of neurons in the central nervous system (CNS). It has been shown that the CSF level of progranulin increases in Alzheimer's disease (AD) patients and is associated with the deposition of amyloid-beta (Aβ) and tau in the brain tissue. In this study, we aimed to assess the longitudinal changes in cerebrospinal fluid (CSF) progranulin levels during different pathophysiological stages of AD and investigate associated AD pathologic features. METHODS We obtained the CSF and neuroimaging data of 1001 subjects from the ADNI database. The participants were classified into four groups based on the A/T/N framework: A + /TN + , A + /TN-, A-/TN + , and A-/TN-. RESULTS Based on our analysis there was a significant difference in CSF progranulin (P = 0.001) between ATN groups. Further ANOVA analysis revealed that there was no significant difference in the rate of change of CSF-progranulin ATN groups. We found that the rate of change of CSF progranulin was associated with baseline Aβ-PET only in the A-/TN + group. A significant association was found between the rate of change of CSF progranulin and the Aβ-PET rate of change only in A-/TN + CONCLUSION: Our findings revealed that an increase in CSF progranulin over time is associated with faster formation of Aβ plaques in patients with only tau pathology based on the A/T/N classification (suspected non-Alzheimer's pathology). Together, our findings showed that the role of progranulin-related microglial activity on AD pathology can be stage-dependent, complicated, and more prominent in non-AD pathologic changes. Thus, there is a need for further studies to consider progranulin-based therapies for AD treatment.
Collapse
Affiliation(s)
- Fardin Nabizadeh
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Neurology, Iran University of Medical Sciences, Tehran, Iran.
| | - Rasa Zafari
- School of Medicine, Tehran University of Medical Science, Tehran, Iran
| |
Collapse
|